k141_21529_6	SARG|gi|542061059|gb|ERI11611.1|	38.1	215	284	316	1.09e-32	121
k141_21529_6	SARG|gi|445996719|ref|WP_000074574.1|	38.4	219	284	309	3.62e-32	119
k141_21529_6	SARG|gi|445996709|ref|WP_000074564.1|	38.2	217	284	309	3.62e-32	119
k141_21529_6	SARG|gi|445996710|ref|WP_000074565.1|	38.2	217	284	309	9.84e-32	118
k141_21529_6	SARG|gi|445996722|ref|WP_000074577.1|	38.4	219	284	309	9.84e-32	118
k141_21529_6	SARG|gi|445996723|ref|WP_000074578.1|	38.4	219	284	309	1.37e-31	118
k141_21529_6	SARG|gi|500448961|gb|EOP61695.1|	37.9	219	284	306	1.81e-31	117
k141_21529_6	SARG|gi|445996724|ref|WP_000074579.1|	37.9	219	284	309	2.68e-31	117
k141_21529_6	SARG|gi|1043490477|ref|WP_065382463.1|	37.9	219	284	309	3.73e-31	117
k141_21529_6	SARG|gi|445996726|ref|WP_000074581.1|	37.9	219	284	309	3.73e-31	117
k141_21529_34	NCBI|XSG12260.1|1|1|drcA|drcA||1|||daptomycin_efflux_ABC_transporter_ATP-binding_protein_DrcA|AMR|peptide	32.1	162	583	255	1.16e-14	73.2
k141_14418_19	megares|MEG_4309|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	31.0	519	544	655	1.40e-70	237
k141_14418_19	megares|MEG_4322|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	31.0	519	544	655	1.95e-70	237
k141_14418_19	megares|MEG_4306|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	31.0	519	544	655	1.95e-70	237
k141_14418_19	megares|MEG_4304|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	30.8	519	544	655	1.95e-70	237
k141_14418_19	SARG|gb|AKA86814|ARO:3003746|optrA	30.8	519	544	655	1.95e-70	237
k141_14418_19	megares|MEG_4313|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	30.8	519	544	655	5.28e-70	236
k141_14418_19	megares|MEG_4307|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	30.8	519	544	655	5.28e-70	236
k141_14418_19	megares|MEG_4312|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	30.8	519	544	655	5.28e-70	236
k141_14418_19	megares|MEG_4315|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	30.8	519	544	655	5.28e-70	236
k141_14418_19	megares|MEG_4318|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	30.8	519	544	655	7.35e-70	235
k141_14418_25	SARG|Q08425	27.0	460	531	641	5.58e-34	135
k141_14418_25	megares|MEG_7181|Drugs|Tetracycline|Tetracycline_resistance_ribosomal_protection_proteins|TETQ_1	27.0	460	531	657	6.07e-34	135
k141_14418_25	SARG|Z21523.gene.p01	27.0	460	531	657	6.07e-34	135
k141_14418_25	NCBI|WP_063856408.1|1|1|tet(Q)|tet(Q)|target_protection|2|TETRACYCLINE|TETRACYCLINE|tetracycline_resistance_ribosomal_protection_protein_Tet(Q)|AMR|tetracycline	27.0	460	531	654	8.06e-34	134
k141_14418_25	megares|MEG_7182|Drugs|Tetracycline|Tetracycline_resistance_ribosomal_protection_proteins|TETQ_1	27.0	460	531	670	8.70e-34	134
k141_14418_25	SARG|AAB51122	27.0	460	531	670	8.70e-34	134
k141_14418_25	SARG|Q52360	26.4	455	531	641	1.11e-32	131
k141_14418_25	SARG|P70882	26.4	455	531	641	1.11e-32	131
k141_14418_25	SARG|BAD46890	26.4	455	531	657	1.19e-32	131
k141_14418_25	NCBI|WP_063856409.1|1|1|tet(Q)|tet(Q)|target_protection|2|TETRACYCLINE|TETRACYCLINE|tetracycline_resistance_ribosomal_protection_protein_Tet(Q)|AMR|tetracycline	25.9	455	531	641	3.64e-32	129
k141_14418_39	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	27.7	119	267	228	1.02e-07	50.4
k141_14418_39	CARD|gb|ATC67679.1|ARO:3000838|arlR	25.2	131	267	219	4.68e-06	45.4
k141_14418_47	megares|MEG_5148|Drugs|beta-lactam|Class_D_betalactamases|OXA_1	27.2	276	294	346	7.26e-19	84.3
k141_14418_78	SARG|gb|AGN74946|ARO:3003749|salA	23.7	518	516	541	4.63e-35	137
k141_14418_78	SARG|gb|ABX00624.1|ARO:3002881|lmrC	26.9	535	516	550	2.72e-33	132
k141_14418_78	NCBI|WP_171943877.1|1|1|vga(F)|vga(F)|target_protection|2|LINCOSAMIDE|LINCOSAMIDE|ABC-F_type_ribosomal_protection_protein_Vga(F)|AMR|lincosamide	24.9	506	516	461	2.23e-28	116
k141_14418_78	SARG|gb|WP_096809342.1|ARO:3007029|salE	22.9	498	516	543	4.41e-28	116
k141_14418_78	NCBI|WP_172065992.1|1|1|vga(F)|vga(F)|target_protection|2|LINCOSAMIDE|LINCOSAMIDE|ABC-F_type_ribosomal_protection_protein_Vga(F)|AMR|lincosamide	24.7	497	516	461	7.48e-28	115
k141_14418_78	SARG|AY004350.gene.p01	23.9	511	516	492	5.73e-23	100
k141_14418_78	SARG|gi|488321355|ref|WP_002390740.1|	25.0	516	516	492	7.67e-23	100
k141_14418_78	SARG|gi|488243106|ref|WP_002314314.1|	24.0	508	516	492	1.03e-22	100
k141_14418_78	SARG|FR772051.1.gene9.p01	36.3	215	516	524	3.87e-22	98.6
k141_14418_78	SARG|gi|488216250|ref|WP_002287458.1|	24.1	507	516	492	1.06e-21	97.1
k141_14418_82	NCBI|WP_032489743.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	39.1	220	228	220	2.65e-55	175
k141_14418_82	NCBI|WP_002317273.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	39.1	220	228	219	3.64e-55	174
k141_14418_82	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	40.9	232	228	231	3.68e-55	175
k141_14418_82	NCBI|WP_063856719.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	39.1	220	228	220	3.75e-55	174
k141_14418_82	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	42.1	233	228	232	1.52e-54	173
k141_14418_82	NCBI|WP_063856723.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	38.6	220	228	219	2.92e-54	172
k141_14418_82	SARG|ZP_02848503	39.2	222	228	221	8.80e-54	171
k141_14418_82	NCBI|WP_002368697.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	38.6	220	228	220	1.21e-53	171
k141_14418_82	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	39.0	228	228	232	6.91e-53	169
k141_14418_82	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	39.0	228	228	232	6.91e-53	169
k141_14418_83	NCBI|WP_002368696.1|1|1|vanS-B|vanS-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-B|AMR|glycopeptide	25.8	322	533	447	1.64e-28	117
k141_14418_83	NCBI|WP_002382867.1|1|1|vanS-B|vanS-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-B|AMR|glycopeptide	25.8	322	533	447	2.50e-27	113
k141_14418_83	NCBI|WP_012579101.1|1|1|vanS-B|vanS-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-B|AMR|glycopeptide	25.8	322	533	447	2.50e-27	113
k141_14418_83	NCBI|WP_063856739.1|1|1|vanS-B|vanS-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-B|AMR|glycopeptide	25.8	322	533	447	2.50e-27	113
k141_14418_83	NCBI|WP_063856751.1|1|1|vanS-B|vanS-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-B|AMR|glycopeptide	25.2	322	533	454	9.79e-26	108
k141_14418_83	NCBI|WP_011461302.1|1|1|vanS-I|vanS-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-I|AMR|glycopeptide	25.6	281	533	392	1.11e-23	102
k141_14418_83	CARD|gb|ADM92606.1|ARO:3000549|adeS	26.6	308	533	361	1.68e-21	95.1
k141_14418_83	megares|MEG_7514|Drugs|Glycopeptide|VanL-type_regulator|VANSL_1	21.8	220	533	364	2.01e-19	89.0
k141_14418_83	NCBI|WP_063856745.1|1|1|vanS-L|vanS-L|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-L|AMR|glycopeptide	21.8	220	533	364	2.01e-19	89.0
k141_14418_83	NCBI|WP_222891058.1|1|1|vanS-P|vanS-P|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-P|AMR|glycopeptide	24.6	232	533	359	8.36e-19	87.0
k141_14418_94	SARG|gb|AAK76137.1|ARO:3000024|patA	35.3	527	583	564	2.95e-102	319
k141_14418_94	SARG|gb|WP_104671188.1|ARO:3003948|efrA	34.5	550	583	575	4.35e-101	317
k141_14418_94	SARG|gb|AYV52072.1|ARO:3002882|lmrD	30.2	487	583	664	1.15e-69	236
k141_14418_94	SARG|gb|AAK76136.1|ARO:3000025|patB	29.6	486	583	588	9.90e-67	226
k141_14418_94	SARG|gi|516574297|ref|WP_017949361.1|	28.3	534	583	620	2.55e-62	215
k141_14418_94	SARG|gi|1045390184|ref|WP_065479071.1|	28.6	528	583	605	2.66e-61	212
k141_14418_94	SARG|gi|739906046|ref|WP_037756452.1|	27.9	534	583	620	4.83e-61	212
k141_14418_94	SARG|gi|764446018|ref|WP_044369325.1|	28.6	528	583	605	2.61e-60	209
k141_14418_94	SARG|gi|948137056|ref|WP_056795395.1|	28.7	529	583	602	4.76e-60	209
k141_14418_94	SARG|gi|664556405|ref|WP_031071225.1|	28.3	534	583	602	4.76e-60	209
k141_14418_95	SARG|gb|AAK76136.1|ARO:3000025|patB	32.2	614	642	588	1.34e-98	312
k141_14418_95	SARG|gb|AYV52072.1|ARO:3002882|lmrD	35.5	516	642	664	1.75e-92	298
k141_14418_95	NCBI|WP_289811733.1|1|1|tetB(60)|tetB(60)||2|TETRACYCLINE|TETRACYCLINE|tetracycline_efflux_ABC_transporter_Tet(60)_subunit_B|AMR|tetracycline	29.0	611	642	579	1.73e-77	256
k141_14418_95	SARG|gi|944009777|ref|WP_055601444.1|	29.6	642	642	628	2.69e-77	257
k141_14418_95	SARG|gi|497748188|ref|WP_010062372.1|	30.1	539	642	605	8.51e-77	255
k141_14418_95	SARG|gi|695887424|ref|WP_032788534.1|	30.0	534	642	605	3.22e-76	254
k141_14418_95	SARG|gb|ANZ79241.1|ARO:3004036|tetB(60)	29.9	586	642	579	3.47e-76	253
k141_14418_95	SARG|gi|664180077|ref|WP_030714054.1|	29.9	539	642	605	4.49e-76	253
k141_14418_95	SARG|gi|695865802|ref|WP_032778631.1|	29.7	539	642	605	6.26e-76	253
k141_14418_95	SARG|gi|1045390184|ref|WP_065479071.1|	30.1	539	642	605	8.73e-76	253
k141_14418_97	SARG|gi|504542119|ref|WP_014729221.1|	36.1	313	1197	647	5.11e-49	184
k141_14418_97	SARG|gi|696420214|ref|WP_032990021.1|	36.1	313	1197	647	6.86e-49	184
k141_14418_97	SARG|gi|851922185|ref|WP_048218206.1|	36.0	314	1197	648	6.96e-49	184
k141_14418_97	SARG|gi|696375069|ref|WP_032949617.1|	36.0	314	1197	648	6.96e-49	184
k141_14418_97	SARG|gi|489127020|ref|WP_003036815.1|	36.0	314	1197	648	6.96e-49	184
k141_14418_97	SARG|gi|938460528|ref|WP_054624864.1|	36.1	313	1197	647	9.21e-49	184
k141_14418_97	SARG|gi|1020141879|ref|WP_063264839.1|	36.1	313	1197	647	9.21e-49	184
k141_14418_97	SARG|gi|490522515|ref|WP_004387938.1|	36.1	313	1197	647	9.21e-49	184
k141_14418_97	SARG|gi|639225329|ref|WP_024561799.1|	35.0	314	1197	648	9.34e-49	184
k141_14418_97	SARG|gi|639218559|ref|WP_024556062.1|	35.0	314	1197	648	9.34e-49	184
k141_14418_214	SARG|gb|ADZ12699.1|ARO:3005091|RanA	31.0	239	358	258	2.36e-31	118
k141_14418_214	SARG|gi|895865878|ref|WP_048974758.1|	35.6	222	358	646	4.25e-28	114
k141_14418_214	SARG|gb|AYV52072.1|ARO:3002882|lmrD	27.7	220	358	664	5.37e-17	81.3
k141_14418_214	SARG|gb|AAK76136.1|ARO:3000025|patB	26.7	217	358	588	3.83e-16	78.6
k141_14418_214	SARG|gb|CDO61516.1|ARO:3003949|efrB	29.5	200	358	362	9.29e-15	73.6
k141_14418_214	NCBI|WP_289811733.1|1|1|tetB(60)|tetB(60)||2|TETRACYCLINE|TETRACYCLINE|tetracycline_efflux_ABC_transporter_Tet(60)_subunit_B|AMR|tetracycline	27.7	224	358	579	9.43e-14	71.2
k141_14418_214	SARG|gb|ANZ79241.1|ARO:3004036|tetB(60)	26.2	225	358	579	4.00e-13	69.3
k141_14418_216	megares|MEG_7603|Drugs|Glycopeptide|VanD-type_accessory_protein|VANYD_1	30.1	266	412	355	4.74e-20	89.7
k141_14418_216	SARG|BAE96115	30.1	266	412	355	4.74e-20	89.7
k141_14418_216	NCBI|WP_063856854.1|1|1|vanY-D|vanY-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|transpeptidase-like_D-Ala-D-Ala_carboxypeptidase_VanY-D|AMR|glycopeptide	29.2	264	412	356	9.87e-19	85.9
k141_14418_216	megares|MEG_7604|Drugs|Glycopeptide|VanD-type_accessory_protein|VANYD_2	31.0	197	412	209	1.06e-14	71.6
k141_14418_217	SARG|ZP_04679156	25.7	440	461	451	2.56e-36	138
k141_14418_217	SARG|gi|505177635|ref|WP_015364737.1|	24.8	440	461	451	3.53e-36	137
k141_14418_217	SARG|gi|488374619|ref|WP_002444004.1|	24.9	429	461	452	6.77e-36	137
k141_14418_217	SARG|gb|CAE00499.1|ARO:3003835|cdeA	25.3	419	461	441	9.27e-34	130
k141_14418_235	NCBI|WP_049151672.1|1|1|pbp2m|pbp2m||2|beta-lactam|beta-lactam|penicillin-binding_protein_PBP2M|AMR|beta-lactam	31.4	334	489	593	1.57e-25	108
k141_14418_235	NCBI|WP_063852710.1|1|1|mecB|mecB|insensitivity|2|METHICILLIN|beta-lactam|PBP2a_family_beta-lactam-resistant_peptidoglycan_transpeptidase_MecB|AMR|beta-lactam	24.8	443	489	674	6.19e-21	95.1
k141_14418_235	SARG|gb|BAI83385.1|ARO:3003440|mecB	26.1	448	489	674	8.24e-21	94.7
k141_14418_235	ResF|penA_1_AF515059_1	24.2	414	489	581	4.30e-14	73.6
k141_14660_2	CARD|gb|ADM92606.1|ARO:3000549|adeS	26.8	209	300	361	5.94e-13	67.4
k141_14660_3	NCBI|XSG12260.1|1|1|drcA|drcA||1|||daptomycin_efflux_ABC_transporter_ATP-binding_protein_DrcA|AMR|peptide	43.3	224	224	255	2.14e-61	191
k141_14660_3	SARG|YP_001176128	47.5	221	224	646	1.29e-57	191
k141_14660_3	SARG|gi|981224618|ref|WP_059445588.1|	46.6	221	224	646	1.79e-57	191
k141_14660_3	SARG|gi|836585048|ref|WP_047742322.1|	46.6	221	224	646	1.79e-57	191
k141_14660_3	SARG|gi|740856590|ref|WP_038641842.1|	46.4	220	224	648	1.84e-57	191
k141_14660_3	SARG|gi|922960663|ref|WP_053388845.1|	46.4	220	224	648	1.84e-57	191
k141_14660_3	SARG|gi|754927849|ref|WP_042284850.1|	45.9	220	224	648	1.84e-57	191
k141_14660_3	SARG|gi|974588181|ref|WP_059178476.1|	47.1	221	224	646	2.50e-57	191
k141_14660_3	SARG|gi|1016275448|gb|AMX06027.1|	46.6	221	224	646	2.50e-57	191
k141_14660_3	SARG|gi|757799695|ref|WP_043016897.1|	46.4	220	224	648	2.57e-57	191
k141_50114_46	SARG|gi|895865878|ref|WP_048974758.1|	32.9	228	244	646	2.36e-20	88.6
k141_50114_46	SARG|gi|542061059|gb|ERI11611.1|	27.8	227	244	316	1.48e-15	73.6
k141_50114_47	NCBI|XSG12260.1|1|1|drcA|drcA||1|||daptomycin_efflux_ABC_transporter_ATP-binding_protein_DrcA|AMR|peptide	31.9	210	293	255	9.19e-26	101
k141_50114_47	SARG|gi|746243059|ref|WP_039291473.1|	32.6	236	293	648	1.16e-25	105
k141_50114_47	SARG|gi|746253210|ref|WP_039301529.1|	32.6	236	293	648	1.57e-25	105
k141_50114_47	SARG|gi|1001720867|ref|WP_061274204.1|	32.6	236	293	648	1.57e-25	105
k141_50114_47	SARG|gi|565651791|ref|WP_023899061.1|	33.8	234	293	647	2.13e-25	104
k141_50114_47	SARG|Q83LR7	32.6	233	293	648	2.13e-25	104
k141_50114_47	SARG|gi|1035670474|ref|WP_064517458.1|	31.9	273	293	648	2.13e-25	104
k141_50114_47	SARG|gi|647325472|ref|WP_025760953.1|	32.6	233	293	648	2.13e-25	104
k141_50114_47	SARG|gi|647323678|ref|WP_025760497.1|	32.6	233	293	648	2.13e-25	104
k141_50114_47	SARG|gi|639209604|ref|WP_024547784.1|	32.9	234	293	648	2.13e-25	104
k141_64120_32	SARG|gb|AAV85982.1|ARO:3000535|macB	30.2	212	366	644	1.01e-17	83.6
k141_64120_32	SARG|gi|507035724|ref|WP_016107411.1|	24.6	203	366	309	2.82e-17	80.5
k141_64120_32	SARG|gi|445996698|ref|WP_000074553.1|	24.6	203	366	309	2.82e-17	80.5
k141_64120_32	SARG|gi|445996697|ref|WP_000074552.1|	24.6	203	366	309	3.82e-17	80.1
k141_64120_32	SARG|gi|445996696|ref|WP_000074551.1|	24.6	203	366	309	3.82e-17	80.1
k141_64120_32	SARG|gi|507023808|ref|WP_016095885.1|	26.1	203	366	309	5.19e-17	79.7
k141_64120_32	SARG|gi|507050365|ref|WP_016121371.1|	25.6	203	366	309	7.05e-17	79.3
k141_64120_32	SARG|gi|488068784|ref|WP_002140181.1|	26.6	203	366	309	7.05e-17	79.3
k141_64120_32	SARG|gi|447057510|ref|WP_001134766.1|	26.1	203	366	309	7.05e-17	79.3
k141_64120_32	SARG|gi|488120365|ref|WP_002191762.1|	26.6	203	366	309	9.56e-17	79.0
k141_64120_53	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	26.4	110	533	228	2.34e-07	50.8
k141_64120_53	CARD|gb|BAB36671.1|ARO:3000832|evgA	28.2	85	533	204	4.72e-06	46.6
k141_64120_55	SARG|gi|446048013|ref|WP_000125868.1|	25.1	243	503	648	5.60e-16	79.7
k141_64120_55	SARG|gb|CDO61516.1|ARO:3003949|efrB	24.9	185	503	362	9.22e-11	62.4
k141_64120_55	SARG|gi|488306124|ref|WP_002376519.1|	24.4	209	503	498	3.98e-09	57.8
k141_64120_55	SARG|gb|WP_096809342.1|ARO:3007029|salE	26.1	188	503	543	9.79e-09	56.6
k141_64120_55	SARG|AXF35727.1	24.2	215	503	497	1.14e-07	53.1
k141_64120_55	SARG|gb|AVI44920.1|ARO:3004470|poxtA	26.5	147	503	542	3.37e-06	48.5
k141_64120_55	NCBI|WP_209691075.1|1|1|poxtA2|poxtA|target_protection|2|CHLORAMPHENICOL/FLORFENICOL/LINEZOLID|OXAZOLIDINONE/PHENICOL|ABC-F_type_ribosomal_protection_protein_PoxtA2|AMR|multidrug	26.5	147	503	544	3.38e-06	48.5
k141_64120_55	NCBI|AJP12342.1|1|1|cplR|cplR|target_protection|1|CLINDAMYCIN/LINCOMYCIN/RETAPAMULIN/VIRGINIAMYCIN|LINCOSAMIDE/PLEUROMUTILIN/STREPTOGRAMIN|ABC-F_type_ribosomal_protection_protein_CplR|AMR|multidrug	22.2	221	503	550	3.39e-06	48.5
k141_64120_55	SARG|gi|488231473|ref|WP_002302681.1|	22.8	215	503	492	4.23e-06	48.1
k141_64120_55	SARG|gi|488216250|ref|WP_002287458.1|	22.8	215	503	492	4.23e-06	48.1
k141_22310_2	SARG|DQ212986.1.gene3.p01	44.4	63	69	75	9.33e-17	66.2
k141_43361_1	SARG|gb|AJP77059|ARO:3003670|PEDO-1	30.4	148	239	286	7.25e-09	53.9
k141_92516_2	NCBI|WP_021418928.1|1|1|vanR-G|vanR-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G|AMR|glycopeptide	40.7	231	224	235	3.04e-48	157
k141_92516_2	CARD|gb|ATC67679.1|ARO:3000838|arlR	40.8	218	224	219	2.75e-45	149
k141_92516_2	NCBI|WP_063856716.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	39.3	229	224	231	9.66e-43	143
k141_92516_2	megares|MEG_7449|Drugs|Glycopeptide|VanA-type_regulator|VANRA_1	38.9	229	224	231	2.72e-42	142
k141_92516_2	NCBI|WP_001280781.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	38.4	229	224	231	1.34e-39	135
k141_92516_2	NCBI|WP_063856721.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	38.0	229	224	231	1.34e-39	135
k141_92516_2	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	34.5	223	224	228	6.91e-39	133
k141_92516_2	NCBI|WP_063856720.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	37.6	229	224	231	1.05e-38	132
k141_92516_2	CARD|gb|AAD51348.1|ARO:3003066|smeR	34.8	224	224	229	3.23e-33	118
k141_92516_2	megares|MEG_3448|Drugs|Aminoglycosides|Aminoglycoside_efflux_pumps|KDPE_1	33.6	223	224	225	1.25e-31	114
k141_92516_4	NCBI|XSG12260.1|1|1|drcA|drcA||1|||daptomycin_efflux_ABC_transporter_ATP-binding_protein_DrcA|AMR|peptide	44.0	216	225	255	1.21e-63	197
k141_92516_4	SARG|gb|AAV85982.1|ARO:3000535|macB	44.2	224	225	644	9.95e-52	176
k141_92516_18	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	44.6	224	230	231	9.03e-62	192
k141_92516_18	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	44.5	229	230	232	3.74e-61	190
k141_92516_18	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	44.5	229	230	232	3.74e-61	190
k141_92516_18	NCBI|AXB64454.1|1|1|vanR-Cd|vanR-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G-Cd|AMR|glycopeptide	44.4	225	230	233	2.50e-59	186
k141_92516_18	NCBI|WP_021418928.1|1|1|vanR-G|vanR-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G|AMR|glycopeptide	44.3	228	230	235	1.21e-57	181
k141_92516_18	NCBI|WP_222891057.1|1|1|vanR-P|vanR-P|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-P|AMR|glycopeptide	44.2	231	230	239	1.37e-57	181
k141_92516_18	NCBI|WP_063856722.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	43.8	226	230	232	1.57e-57	181
k141_92516_18	NCBI|WP_063856715.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	44.7	226	230	232	4.45e-57	180
k141_92516_18	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	43.6	227	230	232	6.30e-57	179
k141_92516_18	NCBI|WP_063856718.1|1|1|vanR-E|vanR-E|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-E|AMR|glycopeptide	40.9	225	230	229	2.31e-56	178
k141_92516_19	NCBI|WP_222891058.1|1|1|vanS-P|vanS-P|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-P|AMR|glycopeptide	31.0	229	505	359	9.95e-25	104
k141_92516_19	NCBI|WP_063856748.1|1|1|vanS-M|vanS-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-M|AMR|glycopeptide	24.8	314	505	370	8.02e-23	99.0
k141_92516_19	SARG|gb|AAG05187.1|ARO:3005067|ParS	27.3	289	505	428	8.07e-23	99.8
k141_92516_19	NCBI|WP_006285582.1|1|1|vanS-F|vanS-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-F|AMR|glycopeptide	24.3	296	505	365	1.13e-21	95.5
k141_92516_19	megares|MEG_7514|Drugs|Glycopeptide|VanL-type_regulator|VANSL_1	23.9	306	505	364	1.89e-18	85.9
k141_92516_19	NCBI|WP_063856745.1|1|1|vanS-L|vanS-L|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-L|AMR|glycopeptide	23.9	306	505	364	1.89e-18	85.9
k141_92516_19	CARD|gb|AEX49906.1|ARO:3003583|basS	23.8	307	505	477	4.01e-18	85.9
k141_92516_43	NCBI|WP_109545033.1|1|1|vanY-D|vanY-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|transpeptidase-like_D-Ala-D-Ala_carboxypeptidase_VanY-D|AMR|glycopeptide	30.8	247	352	355	4.51e-18	83.2
k141_92516_43	megares|MEG_7602|Drugs|Glycopeptide|VanD-type_accessory_protein|VANYD_1	30.8	247	352	355	4.51e-18	83.2
k141_92516_43	SARG|ACM47285	30.8	247	352	363	4.82e-18	83.2
k141_92516_43	NCBI|WP_049898469.1|1|1|vanY-D|vanY-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|transpeptidase-like_D-Ala-D-Ala_carboxypeptidase_VanY-D|AMR|glycopeptide	30.4	227	352	356	1.65e-13	69.7
k141_92516_43	NCBI|WP_063856862.1|1|1|vanY-D|vanY-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|transpeptidase-like_D-Ala-D-Ala_carboxypeptidase_VanY-D|AMR|glycopeptide	30.4	227	352	356	1.65e-13	69.7
k141_78575_2	SARG|gi|895981299|ref|WP_049056431.1|	38.0	221	222	648	1.04e-37	137
k141_78575_2	SARG|gi|823281237|ref|WP_047037467.1|	38.0	221	222	648	1.04e-37	137
k141_78575_2	SARG|gi|895967513|ref|WP_049046752.1|	38.0	221	222	648	1.04e-37	137
k141_78575_2	SARG|gi|779903733|ref|WP_045374054.1|	38.0	221	222	648	1.04e-37	137
k141_78575_2	SARG|gi|782756348|ref|WP_045630015.1|	38.0	221	222	646	1.41e-37	137
k141_78575_2	SARG|gi|754493745|ref|WP_041910640.1|	37.6	221	222	646	1.94e-37	136
k141_78575_2	SARG|gi|498115003|ref|WP_010429159.1|	37.1	221	222	646	3.66e-37	135
k141_78575_2	SARG|gi|695793471|ref|WP_032707680.1|	38.0	221	222	648	3.69e-37	135
k141_78575_2	SARG|gi|896325272|ref|WP_049294291.1|	37.6	221	222	648	3.69e-37	135
k141_78575_2	SARG|gi|823326845|ref|WP_047080664.1|	37.6	221	222	648	5.07e-37	135
k141_78575_3	SARG|gb|AAC74000.1|ARO:3003950|msbA	33.3	273	559	582	5.12e-45	166
k141_78575_3	SARG|gb|ANZ79241.1|ARO:3004036|tetB(60)	25.1	562	559	579	2.85e-40	153
k141_78575_3	NCBI|WP_289811733.1|1|1|tetB(60)|tetB(60)||2|TETRACYCLINE|TETRACYCLINE|tetracycline_efflux_ABC_transporter_Tet(60)_subunit_B|AMR|tetracycline	24.8	557	559	579	4.00e-38	147
k141_78575_3	SARG|gb|WP_104671188.1|ARO:3003948|efrA	24.2	529	559	575	9.67e-38	145
k141_78575_3	SARG|gb|AET10445.1|ARO:3004033|tetB(46)	25.8	414	559	578	9.97e-38	145
k141_78575_3	SARG|gb|CDO61516.1|ARO:3003949|efrB	30.4	280	559	362	5.83e-37	139
k141_78575_3	SARG|gi|1033217078|gb|OAR27197.1|	21.4	548	559	601	1.74e-31	127
k141_78575_3	SARG|gi|1045390184|ref|WP_065479071.1|	20.6	545	559	605	1.79e-31	127
k141_78575_3	SARG|gi|664556405|ref|WP_031071225.1|	21.4	552	559	602	3.17e-31	127
k141_78575_3	SARG|gi|663350985|ref|WP_030349761.1|	25.9	324	559	613	4.54e-31	126
k141_78575_28	SARG|ACF08831	38.3	128	398	639	1.46e-16	80.5
k141_78575_28	NCBI|WP_050824634.1|1|1|tet(O)|tet(O)|target_protection|2|TETRACYCLINE|TETRACYCLINE|tetracycline_resistance_ribosomal_protection_protein_Tet(O)|AMR|tetracycline	38.3	128	398	639	6.17e-16	78.6
k141_78575_29	SARG|NP_348076	27.9	685	706	652	3.54e-75	254
k141_78575_29	SARG|L42544.gene.p01	28.2	667	706	651	1.29e-74	252
k141_78575_29	SARG|AAV80410	28.2	667	706	651	2.49e-74	251
k141_78575_29	SARG|YP_002850805	27.2	684	706	652	6.47e-70	239
k141_78575_29	SARG|ZP_02952732	26.9	684	706	652	1.68e-68	236
k141_78575_29	SARG|ZP_02632674	26.9	684	706	660	1.96e-68	236
k141_78575_29	SARG|L20800.gene.p01	26.9	684	706	652	6.17e-68	234
k141_78575_29	SARG|AJ514254.gene.p01	26.4	692	706	640	2.83e-62	218
k141_78575_29	megares|MEG_7175|Drugs|Tetracycline|Tetracycline_resistance_ribosomal_protection_proteins|TETO_1	26.8	671	706	639	4.72e-60	212
k141_78575_29	NCBI|WP_063856409.1|1|1|tet(Q)|tet(Q)|target_protection|2|TETRACYCLINE|TETRACYCLINE|tetracycline_resistance_ribosomal_protection_protein_Tet(Q)|AMR|tetracycline	25.7	697	706	641	8.67e-59	209
k141_78575_53	NCBI|XSG12260.1|1|1|drcA|drcA||1|||daptomycin_efflux_ABC_transporter_ATP-binding_protein_DrcA|AMR|peptide	28.9	232	338	255	2.18e-28	109
k141_78575_53	SARG|gi|545248218|ref|WP_021546584.1|	28.0	271	338	648	3.28e-24	102
k141_78575_53	SARG|gi|766974935|ref|WP_044866868.1|	30.7	218	338	648	1.47e-23	100
k141_78575_53	SARG|Q83LR7	31.7	218	338	648	2.67e-23	99.8
k141_78575_53	SARG|gi|647325472|ref|WP_025760953.1|	31.7	218	338	648	2.67e-23	99.8
k141_78575_53	SARG|gi|647323678|ref|WP_025760497.1|	31.7	218	338	648	2.67e-23	99.8
k141_78575_53	SARG|gi|446110295|ref|WP_000188150.1|	27.7	271	338	648	2.67e-23	99.8
k141_78575_53	SARG|gi|979505419|ref|WP_059334195.1|	27.7	271	338	648	3.60e-23	99.4
k141_78575_53	SARG|ZP_04001960	27.7	271	338	648	3.60e-23	99.4
k141_78575_53	SARG|gi|545164255|ref|WP_021518974.1|	27.7	271	338	648	3.60e-23	99.4
k141_78575_101	megares|MEG_7505|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	30.7	241	893	381	3.71e-30	122
k141_78575_101	NCBI|WP_063856730.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	30.7	241	893	381	3.71e-30	122
k141_78575_101	NCBI|AXB64455.1|1|1|vanS-Cd|vanS-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|VanG-Cd-type_glycopeptide_resistance_histidine_kinase_VanS|AMR|glycopeptide	31.1	241	893	380	2.20e-29	120
k141_78575_101	megares|MEG_7498|Drugs|Glycopeptide|VanC-type_regulator|VANSC_1	31.1	241	893	380	2.20e-29	120
k141_78575_101	NCBI|WP_023042297.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	29.5	241	893	381	3.02e-29	119
k141_78575_101	megares|MEG_7509|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	29.5	241	893	381	3.02e-29	119
k141_78575_101	NCBI|WP_028530133.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	32.0	225	893	381	4.07e-29	119
k141_78575_101	megares|MEG_7506|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	32.0	225	893	381	4.07e-29	119
k141_78575_101	NCBI|WP_063856748.1|1|1|vanS-M|vanS-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-M|AMR|glycopeptide	29.6	260	893	370	8.28e-29	118
k141_78575_101	NCBI|WP_006285582.1|1|1|vanS-F|vanS-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-F|AMR|glycopeptide	28.6	301	893	365	1.86e-28	117
k141_78575_102	NCBI|WP_222891057.1|1|1|vanR-P|vanR-P|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-P|AMR|glycopeptide	49.1	232	232	239	3.44e-79	236
k141_78575_102	NCBI|AXB64454.1|1|1|vanR-Cd|vanR-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G-Cd|AMR|glycopeptide	48.7	230	232	233	4.63e-78	233
k141_78575_102	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	46.3	229	232	232	1.28e-77	232
k141_78575_102	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	46.3	229	232	232	1.28e-77	232
k141_78575_102	NCBI|WP_021418928.1|1|1|vanR-G|vanR-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G|AMR|glycopeptide	48.1	231	232	235	1.99e-77	232
k141_78575_102	megares|MEG_7449|Drugs|Glycopeptide|VanA-type_regulator|VANRA_1	47.8	228	232	231	4.67e-75	226
k141_78575_102	NCBI|WP_063856716.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	47.8	228	232	231	4.67e-75	226
k141_78575_102	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	45.5	224	232	232	6.83e-75	225
k141_78575_102	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	47.8	224	232	231	2.67e-74	224
k141_78575_102	NCBI|WP_063856721.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	47.4	228	232	231	4.35e-73	221
k141_78575_109	SARG|gi|493394434|ref|WP_006350564.1|	32.7	318	601	602	1.11e-43	164
k141_78575_109	SARG|gi|944009777|ref|WP_055601444.1|	32.9	328	601	628	1.12e-41	158
k141_78575_109	SARG|gi|748767925|ref|WP_040019608.1|	31.8	324	601	623	1.45e-41	158
k141_78575_109	SARG|gi|655413091|ref|WP_028811890.1|	32.6	316	601	603	2.17e-41	157
k141_78575_109	SARG|gi|516574297|ref|WP_017949361.1|	32.4	309	601	620	4.80e-41	156
k141_78575_109	SARG|gi|655401130|ref|WP_028800283.1|	32.5	329	601	599	7.12e-41	155
k141_78575_109	SARG|gi|739906046|ref|WP_037756452.1|	32.4	309	601	620	8.85e-41	155
k141_78575_109	SARG|gi|695842130|ref|WP_032755430.1|	32.1	324	601	603	4.69e-40	153
k141_78575_109	SARG|gi|663350985|ref|WP_030349761.1|	32.3	325	601	613	7.04e-40	153
k141_78575_109	SARG|gi|505420018|ref|WP_015607120.1|	31.8	324	601	603	1.17e-39	152
k141_78575_110	SARG|gb|AAC74000.1|ARO:3003950|msbA	32.0	341	607	582	1.05e-44	166
k141_78575_110	SARG|gi|664556405|ref|WP_031071225.1|	33.4	308	607	602	2.67e-42	160
k141_78575_110	SARG|gi|953808775|ref|WP_058042812.1|	38.1	247	607	608	9.81e-42	158
k141_78575_110	SARG|gi|817122037|ref|WP_046494699.1|	33.1	323	607	613	8.64e-39	150
k141_78575_110	NCBI|WP_011116970.1|1|1|tetAB_B|tetAB_B|efflux|2|TETRACYCLINE|TETRACYCLINE|tetracycline_efflux_ABC_transporter_TetAB_subunit_B|AMR|tetracycline	35.3	215	607	528	1.10e-26	113
k141_78575_115	NCBI|AAD44693.1|1|1|mtrA_Ngon|mtrA_Ngon||1|EFFLUX|EFFLUX|efflux_transporter_MtrCDE_transcriptional_activator_MtrA|AMR|efflux	23.9	159	292	301	6.21e-06	45.8
k141_78575_117	SARG|NP_878015	34.2	257	319	322	2.88e-28	110
k141_78575_117	NCBI|WP_063856710.1|1|1|vanH-Pt2|vanH-Pt2|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|D-lactate_dehydrogenase_VanH-Pt2|AMR|glycopeptide	33.8	240	319	322	1.04e-26	106
k141_78575_117	SARG|AAY52004	33.5	257	319	322	2.00e-26	105
k141_78575_117	NCBI|WP_063856698.1|1|1|vanH-Ac1|vanH-Ac1|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|D-lactate_dehydrogenase_VanH-Ac1|AMR|glycopeptide	32.3	257	319	351	4.31e-26	105
k141_78575_117	megares|MEG_7399|Drugs|Glycopeptide|VanA-type_resistance_protein|VANHA_1	32.7	245	319	237	2.83e-25	100
k141_78575_117	SARG|gi|740152780|ref|WP_037997109.1|	31.6	256	319	322	9.75e-25	100
k141_78575_117	NCBI|WP_063856700.1|1|1|vanH-Ao2|vanH-Ao2|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|D-lactate_dehydrogenase_VanH-Ao2|AMR|glycopeptide	31.5	257	319	343	1.82e-24	100
k141_78575_117	NCBI|WP_063856699.1|1|1|vanH-Ao1|vanH-Ao1|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|D-lactate_dehydrogenase_VanH-Ao1|AMR|glycopeptide	31.5	257	319	348	1.95e-24	100
k141_78575_117	SARG|AAD51059	29.7	276	319	323	8.88e-23	95.5
k141_78575_117	SARG|AAD41881	29.3	276	319	323	8.27e-22	92.8
k141_78575_152	NCBI|CAJ68095.1|1|1|vanZ1|vanZ1|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_protein_VanZ1|AMR|glycopeptide	43.9	155	173	169	2.93e-36	122
k141_78575_152	SARG|CAB61225	39.2	148	173	161	1.20e-24	92.8
k141_78575_152	SARG|ACP19239	37.2	148	173	161	4.74e-24	91.3
k141_78575_152	megares|MEG_7452|Drugs|Glycopeptide|VanA-type_regulator|VANRA_1	37.2	148	173	161	4.74e-24	91.3
k141_78575_152	SARG|AF155139.2.gene5.p01	30.7	114	173	206	9.54e-09	51.6
k141_78575_152	SARG|gi|670466162|ref|WP_031414939.1|	32.0	100	173	206	5.78e-07	46.6
k141_78575_152	SARG|gi|515720450|ref|WP_017153050.1|	32.4	105	173	210	5.95e-07	46.6
k141_78575_152	SARG|gi|1028848471|ref|WP_064017434.1|	32.0	100	173	206	1.48e-06	45.4
k141_92841_3	SARG|gb|AAC74000.1|ARO:3003950|msbA	31.7	486	580	582	1.85e-53	190
k141_92841_3	SARG|gi|930482089|ref|WP_054228897.1|	33.1	378	580	599	2.04e-46	171
k141_92841_3	SARG|gi|985844137|ref|WP_060895163.1|	33.1	378	580	599	2.04e-46	171
k141_92841_3	SARG|gi|1045390184|ref|WP_065479071.1|	35.3	360	580	605	7.76e-46	169
k141_92841_3	SARG|gi|1011969930|ref|WP_062776015.1|	34.1	390	580	601	1.38e-45	169
k141_92841_3	SARG|gi|951183771|ref|WP_057661487.1|	35.6	360	580	603	1.42e-45	169
k141_92841_3	SARG|gi|948040364|ref|WP_056699531.1|	35.6	360	580	603	1.42e-45	169
k141_92841_3	SARG|gi|943938624|ref|WP_055567802.1|	34.8	374	580	602	1.92e-45	168
k141_92841_3	SARG|gi|664170108|ref|WP_030704355.1|	37.7	310	580	603	1.94e-45	168
k141_92841_3	SARG|gi|490068471|ref|WP_003970646.1|	37.7	310	580	603	1.94e-45	168
k141_92841_4	SARG|gb|AAC74000.1|ARO:3003950|msbA	30.5	511	577	582	2.76e-57	201
k141_92841_4	SARG|gi|505420018|ref|WP_015607120.1|	37.1	313	577	603	2.20e-51	185
k141_92841_4	SARG|gi|695842130|ref|WP_032755430.1|	37.1	313	577	603	4.17e-51	184
k141_92841_4	SARG|gi|926376632|ref|WP_053705806.1|	36.6	309	577	620	1.39e-50	183
k141_92841_4	SARG|gi|943896259|ref|WP_055534530.1|	35.8	310	577	601	2.00e-50	182
k141_92841_4	SARG|gi|799286378|ref|WP_045936958.1|	36.6	309	577	620	2.63e-50	182
k141_92841_4	SARG|gi|917127754|ref|WP_051734466.1|	36.6	309	577	620	2.63e-50	182
k141_92841_4	SARG|gi|926294973|ref|WP_053631154.1|	36.6	309	577	620	2.63e-50	182
k141_92841_4	SARG|gi|772774655|ref|WP_045322518.1|	36.2	309	577	620	2.63e-50	182
k141_92841_4	SARG|gi|943909899|ref|WP_055545300.1|	36.3	314	577	601	2.75e-50	182
k141_92841_11	NCBI|CCA59315.1|1|1|helR|helR||1|rifamycin|rifamycin|RNA_polymerase_recycling_motor_ATPase_HelR|AMR|rifamycin	32.8	189	684	722	3.21e-20	94.4
k141_92841_25	NCBI|WP_002294513.1|1|1|lsa(E)|lsa(E)|target_protection|2|LINCOSAMIDE/STREPTOGRAMIN|LINCOSAMIDE/STREPTOGRAMIN|ABC-F_type_ribosomal_protection_protein_Lsa(E)|AMR|multidrug	27.5	193	236	494	1.98e-14	70.9
k141_92841_25	NCBI|WP_002389535.1|1|1|bcrA_Lm|bcrA_Lm||2|peptide|peptide|peptide_resistance_ABC_transporter_ATP-binding_subunit_BcrA|AMR|peptide	24.0	225	236	307	6.92e-14	68.6
k141_92841_25	megares|MEG_4322|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	29.9	214	236	655	6.63e-12	63.5
k141_92841_25	SARG|gb|AET10444.1|ARO:3004032|tetA(46)	28.0	218	236	574	1.16e-11	62.8
k141_92841_25	megares|MEG_4321|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	29.9	214	236	655	1.63e-11	62.4
k141_92841_25	megares|MEG_4317|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	29.9	214	236	655	1.63e-11	62.4
k141_92841_25	megares|MEG_4314|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	29.9	214	236	655	1.63e-11	62.4
k141_92841_25	megares|MEG_4323|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	29.9	214	236	655	1.63e-11	62.4
k141_92841_25	megares|MEG_4319|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	29.9	214	236	655	1.63e-11	62.4
k141_92841_25	megares|MEG_4316|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	29.9	214	236	655	1.63e-11	62.4
k141_92841_27	NCBI|WP_289811733.1|1|1|tetB(60)|tetB(60)||2|TETRACYCLINE|TETRACYCLINE|tetracycline_efflux_ABC_transporter_Tet(60)_subunit_B|AMR|tetracycline	34.7	576	595	579	1.61e-102	321
k141_92841_27	SARG|gb|AAK76136.1|ARO:3000025|patB	34.4	590	595	588	5.18e-99	312
k141_92841_27	SARG|gb|ANZ79241.1|ARO:3004036|tetB(60)	34.8	587	595	579	8.72e-98	308
k141_92841_27	SARG|gi|664556405|ref|WP_031071225.1|	34.6	583	595	602	2.80e-94	300
k141_92841_27	SARG|gi|695842130|ref|WP_032755430.1|	33.7	590	595	603	8.51e-93	296
k141_92841_27	SARG|gi|505420018|ref|WP_015607120.1|	33.7	590	595	603	8.51e-93	296
k141_92841_27	SARG|gi|921231571|ref|WP_053176464.1|	33.7	573	595	620	3.60e-92	295
k141_92841_27	SARG|gi|928900436|ref|WP_053931243.1|	33.2	575	595	600	4.29e-92	294
k141_92841_27	SARG|gi|664579989|ref|WP_031094015.1|	33.2	575	595	601	4.40e-92	294
k141_92841_27	SARG|gi|917172177|ref|WP_051778889.1|	33.7	573	595	620	5.05e-92	295
k141_92841_28	SARG|gb|AAC74000.1|ARO:3003950|msbA	32.1	502	588	582	1.33e-78	258
k141_92841_28	SARG|gi|648667297|ref|WP_026359044.1|	31.2	542	588	605	8.64e-78	256
k141_92841_28	SARG|gi|664579989|ref|WP_031094015.1|	30.4	559	588	601	4.36e-76	252
k141_92841_28	SARG|gi|695842130|ref|WP_032755430.1|	30.7	550	588	603	4.56e-76	252
k141_92841_28	SARG|gi|664317010|ref|WP_030845774.1|	30.3	542	588	605	6.66e-76	251
k141_92841_28	SARG|gi|663286402|ref|WP_030292859.1|	30.3	542	588	605	6.66e-76	251
k141_92841_28	SARG|gi|663342223|ref|WP_030341347.1|	30.3	542	588	605	6.66e-76	251
k141_92841_28	SARG|gi|759527374|ref|WP_043247487.1|	30.3	542	588	605	6.66e-76	251
k141_92841_28	SARG|gi|928900436|ref|WP_053931243.1|	30.4	542	588	600	8.32e-76	251
k141_92841_28	SARG|gi|663155409|ref|WP_030194633.1|	30.3	542	588	605	9.30e-76	251
k141_92841_40	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	43.6	225	230	228	3.04e-59	185
k141_92841_40	NCBI|AXB64454.1|1|1|vanR-Cd|vanR-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G-Cd|AMR|glycopeptide	45.4	229	230	233	1.00e-58	184
k141_92841_40	NCBI|WP_005228837.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	43.0	230	230	231	5.38e-58	182
k141_92841_40	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	42.8	229	230	232	5.54e-58	182
k141_92841_40	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	42.4	229	230	232	1.57e-57	181
k141_92841_40	CARD|gb|ATC67679.1|ARO:3000838|arlR	41.9	222	230	219	6.02e-57	179
k141_92841_40	NCBI|WP_063856725.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	42.6	230	230	231	6.12e-57	179
k141_92841_40	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	41.9	227	230	232	6.30e-57	179
k141_92841_40	NCBI|WP_034872470.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	42.6	230	230	231	8.66e-57	179
k141_92841_40	NCBI|WP_063856724.1|1|1|vanR-L|vanR-L|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-L|AMR|glycopeptide	42.6	230	230	231	1.73e-56	178
k141_92841_41	NCBI|WP_063856748.1|1|1|vanS-M|vanS-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-M|AMR|glycopeptide	24.8	286	493	370	1.43e-24	103
k141_64799_6	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	30.4	112	499	228	1.69e-06	48.1
k141_64799_6	CARD|gb|BAB36671.1|ARO:3000832|evgA	27.9	86	499	204	4.34e-06	46.6
k141_64799_36	NCBI|XSG12260.1|1|1|drcA|drcA||1|||daptomycin_efflux_ABC_transporter_ATP-binding_protein_DrcA|AMR|peptide	32.6	239	261	255	4.64e-25	99.0
k141_64799_36	SARG|gi|447057510|ref|WP_001134766.1|	27.6	228	261	309	5.39e-16	75.1
k141_64799_36	SARG|gi|488120365|ref|WP_002191762.1|	25.4	244	261	309	1.88e-15	73.6
k141_64799_36	SARG|gi|542061059|gb|ERI11611.1|	26.1	245	261	316	2.00e-15	73.6
k141_64799_36	SARG|gi|507050365|ref|WP_016121371.1|	25.4	244	261	309	6.55e-15	72.0
k141_64799_36	SARG|gi|507055561|ref|WP_016126482.1|	27.2	228	261	309	8.94e-15	71.6
k141_64799_36	SARG|gi|488053456|ref|WP_002124853.1|	27.2	228	261	309	8.94e-15	71.6
k141_64799_36	SARG|gi|488068784|ref|WP_002140181.1|	27.2	228	261	309	8.94e-15	71.6
k141_64799_36	SARG|gi|488067981|ref|WP_002139378.1|	27.2	228	261	309	1.66e-14	70.9
k141_64799_36	SARG|gi|488130770|ref|WP_002201978.1|	27.2	228	261	309	1.66e-14	70.9
k141_64799_37	SARG|gb|APB03214.1|ARO:3003980|tetA(48)	31.4	226	253	343	4.00e-22	92.4
k141_64799_37	SARG|gi|817122037|ref|WP_046494699.1|	30.6	222	253	613	4.05e-17	79.3
k141_64799_53	SARG|gb|CAE00499.1|ARO:3003835|cdeA	26.4	425	458	441	3.86e-48	170
k141_64799_53	SARG|gi|505177635|ref|WP_015364737.1|	26.1	433	458	451	9.93e-38	142
k141_64799_61	NCBI|WP_000163435.1|1|1|mupA|mupA|insensitivity|2|mupirocin|mupirocin|mupirocin-resistant_isoleucine--tRNA_ligase_MupA|AMR|mupirocin	24.8	819	884	1024	1.06e-67	243
k141_64799_61	megares|MEG_4089|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPA_1	24.8	819	884	1024	1.06e-67	243
k141_64799_61	megares|MEG_4090|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPA_1	24.8	819	884	1024	3.58e-67	241
k141_64799_61	SARG|gb|CAA53189|ARO:3000521|mupA	24.8	819	884	1024	3.58e-67	241
k141_64799_84	SARG|gb|APB03216.1|ARO:3003982|LlmA	61.7	287	289	287	5.87e-142	400
k141_64799_89	megares|MEG_7572|Drugs|Glycopeptide|VanM-type_resistance_protein|VANXM_2	37.4	454	460	481	1.11e-89	280
k141_64799_89	megares|MEG_7563|Drugs|Glycopeptide|VanB-type_resistance_protein|VANXB_2	37.3	453	460	451	1.28e-86	271
k141_64799_89	megares|MEG_7571|Drugs|Glycopeptide|VanM-type_resistance_protein|VANXM_2	36.5	458	460	451	1.21e-83	263
k141_2436_1	megares|MEG_4304|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	35.3	496	519	655	3.06e-95	301
k141_2436_1	SARG|gb|AKA86814|ARO:3003746|optrA	35.3	496	519	655	3.06e-95	301
k141_2436_1	megares|MEG_4313|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	35.3	496	519	655	8.46e-95	300
k141_2436_1	megares|MEG_4312|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	35.3	496	519	655	8.46e-95	300
k141_2436_1	megares|MEG_4315|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	35.3	496	519	655	8.46e-95	300
k141_2436_1	megares|MEG_4307|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	35.3	496	519	655	1.19e-94	300
k141_2436_1	megares|MEG_4323|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	35.3	496	519	655	1.67e-94	300
k141_2436_1	megares|MEG_4309|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	35.1	496	519	655	3.29e-94	299
k141_2436_1	megares|MEG_4318|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	35.1	496	519	655	6.48e-94	298
k141_2436_1	megares|MEG_4306|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	35.1	496	519	655	6.48e-94	298
k141_2436_52	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	31.2	93	102	231	5.32e-11	55.8
k141_2436_52	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	32.3	93	102	232	3.78e-10	53.5
k141_2436_52	CARD|gb|ATC67679.1|ARO:3000838|arlR	30.2	86	102	219	1.26e-09	52.0
k141_2436_52	CARD|gb|AAG06465.1|ARO:3005063|cprR	31.8	88	102	223	1.25e-08	49.3
k141_2436_52	CARD|gb|ADM92605.1|ARO:3000553|adeR	32.5	83	102	247	8.75e-07	44.3
k141_2436_54	megares|MEG_7514|Drugs|Glycopeptide|VanL-type_regulator|VANSL_1	24.8	238	730	364	1.69e-11	65.5
k141_2436_54	NCBI|WP_063856745.1|1|1|vanS-L|vanS-L|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-L|AMR|glycopeptide	24.8	238	730	364	1.69e-11	65.5
k141_2436_54	NCBI|WP_222891058.1|1|1|vanS-P|vanS-P|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-P|AMR|glycopeptide	22.5	280	730	359	3.86e-11	64.3
k141_2436_54	CARD|gb|AEX49906.1|ARO:3003583|basS	27.2	206	730	477	1.40e-10	63.2
k141_2436_54	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	29.8	121	730	231	7.68e-09	55.8
k141_2436_54	CARD|gb|ATC67679.1|ARO:3000838|arlR	29.7	128	730	219	2.17e-08	54.3
k141_2436_54	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	30.8	107	730	232	2.71e-07	51.2
k141_2436_54	CARD|gb|AAG06465.1|ARO:3005063|cprR	27.4	113	730	223	1.08e-06	49.3
k141_2436_57	NCBI|WP_256875606.1|1|1|blaNWM-1|blaNWM|hydrolase|2|CARBAPENEM|beta-lactam|subclass_B3_metallo-beta-lactamase_NWM-1|AMR|beta-lactam	31.3	80	266	310	1.62e-06	47.4
k141_2436_61	SARG|gi|985522333|ref|WP_060811962.1|	39.1	289	331	323	2.09e-61	197
k141_2436_61	SARG|gi|498515089|ref|WP_010815296.1|	38.8	289	331	323	1.16e-60	196
k141_2436_61	SARG|Q47748	39.1	289	331	323	1.16e-60	196
k141_2436_61	SARG|gb|AAB05626.1|ARO:3002943|vanHB	39.1	289	331	323	1.16e-60	196
k141_2436_61	SARG|YP_002333394	39.1	289	331	323	4.60e-60	194
k141_2436_61	NCBI|WP_063856701.1|1|1|vanH-B|vanH-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|D-lactate_dehydrogenase_VanH-B|AMR|glycopeptide	39.1	289	331	323	4.60e-60	194
k141_2436_61	SARG|AF310956.2.gene5.p01	39.1	289	331	323	6.48e-60	194
k141_2436_61	SARG|DQ018711.1.gene4.p01	35.0	317	331	322	2.75e-58	189
k141_2436_61	NCBI|WP_063856700.1|1|1|vanH-Ao2|vanH-Ao2|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|D-lactate_dehydrogenase_VanH-Ao2|AMR|glycopeptide	40.5	259	331	343	1.35e-57	188
k141_2436_61	SARG|gi|737310392|ref|WP_035293250.1|	35.0	317	331	323	1.57e-57	187
k141_2436_72	SARG|gi|664556405|ref|WP_031071225.1|	34.3	575	586	602	7.63e-104	325
k141_2436_72	SARG|gi|505420018|ref|WP_015607120.1|	33.2	573	586	603	3.34e-102	320
k141_2436_72	SARG|AF170880.4.gene1.p01	33.9	575	586	615	6.45e-102	320
k141_2436_72	SARG|gi|695865802|ref|WP_032778631.1|	32.6	577	586	605	6.95e-102	320
k141_2436_72	SARG|gi|695842130|ref|WP_032755430.1|	33.2	573	586	603	9.27e-102	319
k141_2436_72	SARG|gi|558888514|ref|WP_023543283.1|	33.7	575	586	615	1.79e-101	319
k141_2436_72	SARG|gi|664042835|ref|WP_030582300.1|	33.6	571	586	604	1.88e-101	318
k141_2436_72	SARG|gi|1045390184|ref|WP_065479071.1|	32.8	576	586	605	1.93e-101	318
k141_2436_72	SARG|gi|664180077|ref|WP_030714054.1|	32.7	571	586	605	5.37e-101	317
k141_2436_72	SARG|gi|928900436|ref|WP_053931243.1|	32.8	579	586	600	6.61e-101	317
k141_2436_73	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	25.0	104	483	231	1.97e-08	53.9
k141_2436_75	SARG|gb|AAK76137.1|ARO:3000024|patA	27.0	248	273	564	2.10e-15	74.7
k141_2436_75	SARG|gb|WP_104671188.1|ARO:3003948|efrA	27.7	231	273	575	1.71e-14	72.0
k141_2436_75	SARG|gi|655413091|ref|WP_028811890.1|	26.8	235	273	603	6.16e-13	67.4
k141_2436_75	SARG|gi|930482089|ref|WP_054228897.1|	25.3	233	273	599	8.26e-13	67.0
k141_2436_75	SARG|gi|985844137|ref|WP_060895163.1|	25.3	233	273	599	8.26e-13	67.0
k141_2436_75	SARG|gi|493394434|ref|WP_006350564.1|	25.2	234	273	602	8.28e-13	67.0
k141_2436_75	SARG|gi|739906046|ref|WP_037756452.1|	25.3	229	273	620	2.73e-12	65.5
k141_2436_75	SARG|gi|516574297|ref|WP_017949361.1|	25.3	229	273	620	2.73e-12	65.5
k141_2436_75	SARG|gi|943938624|ref|WP_055567802.1|	25.5	235	273	602	4.88e-12	64.7
k141_2436_75	SARG|gi|928900436|ref|WP_053931243.1|	25.0	232	273	600	6.55e-12	64.3
k141_2436_76	SARG|YP_001571041	30.6	242	336	648	2.07e-18	85.1
k141_2436_76	SARG|gi|960873409|ref|WP_058345546.1|	30.6	242	336	648	2.07e-18	85.1
k141_2436_76	SARG|gi|740610794|ref|WP_038396317.1|	30.6	242	336	648	5.02e-18	84.0
k141_2436_76	SARG|gi|922019548|ref|WP_053299973.1|	31.0	242	336	648	2.19e-17	82.0
k141_2436_76	SARG|gi|919601241|ref|WP_052893936.1|	30.6	242	336	648	3.95e-17	81.3
k141_2436_76	SARG|ZP_03074747	30.6	242	336	648	3.95e-17	81.3
k141_2436_76	SARG|gi|923061916|ref|WP_053445667.1|	30.6	242	336	648	3.95e-17	81.3
k141_2436_76	SARG|gi|555268367|ref|WP_023249730.1|	30.6	242	336	648	5.30e-17	80.9
k141_2436_76	SARG|gi|1005616587|ref|WP_061695226.1|	30.6	242	336	648	5.30e-17	80.9
k141_2436_76	SARG|gi|1027935297|ref|WP_063809363.1|	30.6	242	336	648	5.30e-17	80.9
k141_2436_84	SARG|HE999704.1.gene3064.p01	22.0	168	445	241	6.34e-08	52.4
k141_65118_1	SARG|gi|696411918|ref|WP_032982657.1|	41.2	233	233	647	1.82e-56	189
k141_65118_1	SARG|gi|696402390|ref|WP_032974230.1|	41.2	233	233	647	1.82e-56	189
k141_65118_1	SARG|gi|696423952|ref|WP_032993748.1|	41.2	233	233	647	1.82e-56	189
k141_65118_1	SARG|gi|494938585|ref|WP_007664615.1|	40.8	233	233	647	2.54e-56	188
k141_65118_1	SARG|gi|1035670474|ref|WP_064517458.1|	41.3	230	233	648	2.57e-56	188
k141_65118_1	SARG|gi|974588181|ref|WP_059178476.1|	43.0	221	233	646	4.86e-56	187
k141_65118_1	SARG|gi|495067432|ref|WP_007792257.1|	41.2	233	233	647	4.93e-56	187
k141_65118_1	SARG|gi|803568669|ref|WP_046077412.1|	42.5	221	233	648	4.99e-56	187
k141_65118_1	SARG|gi|446110352|ref|WP_000188207.1|	42.5	221	233	648	4.99e-56	187
k141_65118_1	SARG|YP_002382193	42.5	221	233	648	4.99e-56	187
k141_65118_4	SARG|gi|313614636|gb|EFR88215.1|	25.3	442	443	453	1.39e-29	119
k141_65118_4	SARG|gi|313638554|gb|EFS03703.1|	23.9	440	443	453	2.59e-29	118
k141_65118_4	SARG|HE999704.1.gene1126.p01	25.3	293	443	337	4.40e-23	98.6
k141_65118_4	SARG|gi|441473784|emb|CCQ23538.1|	25.3	293	443	336	1.73e-21	94.0
k141_65118_4	SARG|gi|984518628|emb|CUM21384.1|	25.2	329	443	341	8.48e-21	92.0
k141_65118_4	SARG|gi|313619623|gb|EFR91268.1|	27.2	243	443	237	3.12e-15	73.9
k141_65118_4	SARG|gi|313609598|gb|EFR85124.1|	26.5	223	443	226	2.78e-12	65.1
k141_65118_5	NCBI|AXB64454.1|1|1|vanR-Cd|vanR-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G-Cd|AMR|glycopeptide	54.1	231	233	233	1.25e-85	253
k141_65118_5	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	51.8	228	233	232	3.44e-85	251
k141_65118_5	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	51.8	228	233	232	3.44e-85	251
k141_65118_5	NCBI|WP_021418928.1|1|1|vanR-G|vanR-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G|AMR|glycopeptide	53.9	230	233	235	5.39e-85	251
k141_65118_5	NCBI|WP_222891057.1|1|1|vanR-P|vanR-P|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-P|AMR|glycopeptide	53.2	231	233	239	1.65e-82	245
k141_65118_5	NCBI|WP_063856715.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	52.4	229	233	232	1.23e-80	240
k141_65118_5	NCBI|WP_023042613.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	51.3	230	233	232	2.47e-80	239
k141_65118_5	NCBI|WP_063856727.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	50.9	230	233	232	4.96e-80	238
k141_65118_5	NCBI|WP_016295750.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	50.9	230	233	232	7.04e-80	238
k141_65118_5	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	49.6	232	233	231	1.37e-79	237
k141_65118_6	NCBI|WP_006285582.1|1|1|vanS-F|vanS-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-F|AMR|glycopeptide	37.9	290	366	365	3.60e-64	207
k141_65118_6	NCBI|WP_063856748.1|1|1|vanS-M|vanS-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-M|AMR|glycopeptide	37.2	288	366	370	5.90e-60	196
k141_65118_6	megares|MEG_7505|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	38.2	293	366	381	2.98e-55	184
k141_65118_6	NCBI|WP_063856730.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	38.2	293	366	381	2.98e-55	184
k141_65118_6	NCBI|WP_023042297.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	38.0	292	366	381	4.18e-55	184
k141_65118_6	megares|MEG_7509|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	38.0	292	366	381	4.18e-55	184
k141_65118_6	NCBI|WP_028530133.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	37.9	293	366	381	5.88e-55	184
k141_65118_6	megares|MEG_7506|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	37.9	293	366	381	5.88e-55	184
k141_65118_6	megares|MEG_7507|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	38.2	283	366	381	5.88e-55	184
k141_65118_6	NCBI|WP_063856738.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	38.2	283	366	381	5.88e-55	184
k141_65118_8	SARG|gi|542061059|gb|ERI11611.1|	36.7	305	324	316	9.29e-48	162
k141_65118_8	SARG|ABB80128	36.1	305	324	306	2.81e-47	160
k141_65118_8	SARG|P42332	35.7	305	324	306	7.80e-47	159
k141_65118_8	megares|MEG_1213|Drugs|Bacitracin|Bacitracin_ABC_transporter|BCRA_1	35.7	305	324	306	7.80e-47	159
k141_65118_8	SARG|gi|510143239|gb|AGN36970.1|	35.7	305	324	313	9.32e-47	159
k141_65118_8	SARG|AAD21213	35.4	305	324	306	2.17e-46	158
k141_65118_8	SARG|gi|445996710|ref|WP_000074565.1|	35.9	306	324	309	4.61e-46	157
k141_65118_8	SARG|gi|895736250|emb|COF64653.1|	35.9	306	324	309	9.10e-46	156
k141_65118_8	SARG|gi|507023808|ref|WP_016095885.1|	35.9	309	324	309	9.10e-46	156
k141_65118_8	SARG|gi|445996714|ref|WP_000074569.1|	35.9	306	324	309	9.10e-46	156
k141_65118_14	megares|MEG_5396|Drugs|Aminocoumarins|Aminocoumarin-resistant_DNA_topoisomerases|PARY_1	38.3	695	642	703	4.58e-139	421
k141_65118_19	SARG|gb|SOX29786.1|ARO:3004730|tva(A)	25.2	206	257	505	2.24e-10	59.3
k141_65118_19	NCBI|WP_014936356.1|1|1|tva(B)|tva(B)|target_protection|2|TIAMULIN|PLEUROMUTILIN|ABC-F_type_ribosomal_protection_protein_Tva(B)|AMR|pleuromutilin	27.7	191	257	504	4.04e-10	58.5
k141_65118_32	CARD|gb|AAC75429.1|ARO:3000833|evgS	29.3	379	749	1197	4.30e-39	155
k141_65118_32	NCBI|WP_222891058.1|1|1|vanS-P|vanS-P|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-P|AMR|glycopeptide	26.4	235	749	359	5.03e-17	82.4
k141_65118_32	NCBI|WP_011461302.1|1|1|vanS-I|vanS-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-I|AMR|glycopeptide	26.1	249	749	392	1.22e-15	78.6
k141_65118_32	megares|MEG_7514|Drugs|Glycopeptide|VanL-type_regulator|VANSL_1	23.2	224	749	364	3.14e-14	73.9
k141_65118_32	NCBI|WP_063856745.1|1|1|vanS-L|vanS-L|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-L|AMR|glycopeptide	23.2	224	749	364	3.14e-14	73.9
k141_65118_32	megares|MEG_7500|Drugs|Glycopeptide|VanC-type_regulator|VANSC_1	22.9	223	749	352	2.16e-13	71.2
k141_65118_32	megares|MEG_7501|Drugs|Glycopeptide|VanC-type_regulator|VANSC_1	22.9	223	749	354	2.20e-13	71.2
k141_65118_32	megares|MEG_7497|Drugs|Glycopeptide|VanC-type_regulator|VANSC_1	22.9	223	749	376	4.56e-13	70.5
k141_65118_32	NCBI|WP_034869172.1|1|1|vanS-C|vanS-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-C|AMR|glycopeptide	22.9	223	749	376	4.56e-13	70.5
k141_65118_32	megares|MEG_7503|Drugs|Glycopeptide|VanC-type_regulator|VANSC_1	22.0	223	749	354	3.92e-12	67.4
k141_65118_34	CARD|gb|AAC75429.1|ARO:3000833|evgS	29.1	374	719	1197	1.89e-39	155
k141_65118_34	NCBI|WP_023042297.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	27.0	241	719	381	1.88e-15	77.8
k141_65118_34	megares|MEG_7509|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	27.0	241	719	381	1.88e-15	77.8
k141_65118_34	megares|MEG_7507|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	27.0	241	719	381	4.47e-15	76.6
k141_65118_34	NCBI|WP_063856738.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	27.0	241	719	381	4.47e-15	76.6
k141_65118_34	megares|MEG_7505|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	26.6	241	719	381	1.06e-14	75.5
k141_65118_34	NCBI|WP_063856730.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	26.6	241	719	381	1.06e-14	75.5
k141_65118_34	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	33.6	125	719	232	4.78e-14	71.2
k141_65118_34	megares|MEG_7501|Drugs|Glycopeptide|VanC-type_regulator|VANSC_1	24.2	264	719	354	4.87e-14	73.2
k141_65118_34	NCBI|WP_028530133.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	26.6	241	719	381	5.96e-14	73.2
k141_65118_39	SARG|gi|445996719|ref|WP_000074574.1|	34.5	278	305	309	2.13e-40	142
k141_65118_39	SARG|gi|500194536|ref|WP_011867743.1|	34.4	279	305	306	2.12e-39	139
k141_65118_39	megares|MEG_2670|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|DRRA_1	38.6	202	305	293	2.19e-39	139
k141_65118_39	SARG|gi|445996732|ref|WP_000074587.1|	34.5	278	305	309	2.27e-39	139
k141_65118_39	SARG|gi|445996723|ref|WP_000074578.1|	34.2	278	305	309	2.27e-39	139
k141_65118_39	SARG|gi|445996697|ref|WP_000074552.1|	34.5	278	305	309	3.18e-39	139
k141_65118_39	SARG|gi|445996722|ref|WP_000074577.1|	34.2	278	305	309	3.18e-39	139
k141_65118_39	SARG|gi|445996696|ref|WP_000074551.1|	34.5	278	305	309	3.18e-39	139
k141_65118_39	SARG|gi|1043490477|ref|WP_065382463.1|	33.8	278	305	309	6.24e-39	138
k141_65118_39	SARG|gi|445996726|ref|WP_000074581.1|	33.8	278	305	309	6.24e-39	138
k141_58160_22	SARG|gb|BAG33043.1|ARO:3003920|pgpB	28.9	173	174	236	2.31e-08	50.8
k141_58160_22	megares|MEG_5776|Drugs|Lipopeptide|Lipid_A_phosphatase|PGBB_1	28.9	173	174	236	2.31e-08	50.8
k141_79841_11	SARG|gb|AAK76136.1|ARO:3000025|patB	35.3	572	585	588	2.32e-97	307
k141_79841_11	SARG|gb|AYV52072.1|ARO:3002882|lmrD	36.9	507	585	664	4.70e-95	303
k141_79841_11	SARG|gb|CDO61516.1|ARO:3003949|efrB	43.5	333	585	362	9.38e-85	267
k141_79841_11	SARG|gb|ANZ79241.1|ARO:3004036|tetB(60)	30.2	577	585	579	5.89e-79	259
k141_79841_11	NCBI|WP_289811733.1|1|1|tetB(60)|tetB(60)||2|TETRACYCLINE|TETRACYCLINE|tetracycline_efflux_ABC_transporter_Tet(60)_subunit_B|AMR|tetracycline	29.2	575	585	579	3.30e-77	254
k141_79841_11	SARG|gi|928900436|ref|WP_053931243.1|	31.7	515	585	600	8.00e-75	248
k141_79841_11	SARG|gi|664579989|ref|WP_031094015.1|	31.7	515	585	601	8.18e-75	248
k141_79841_11	SARG|gi|860594225|ref|WP_048475168.1|	29.9	579	585	620	6.53e-74	246
k141_79841_11	SARG|gi|926376632|ref|WP_053705806.1|	31.9	505	585	620	6.53e-74	246
k141_79841_11	SARG|gi|926294973|ref|WP_053631154.1|	31.9	505	585	620	6.53e-74	246
k141_79841_12	SARG|gb|WP_104671188.1|ARO:3003948|efrA	37.3	553	587	575	8.53e-110	339
k141_79841_12	SARG|gb|AAK76137.1|ARO:3000024|patA	33.6	568	587	564	2.37e-89	286
k141_79841_12	SARG|gb|ANZ79240.1|ARO:3004035|tetA(60)	31.3	467	587	579	3.42e-62	214
k141_79841_12	SARG|gb|AAC74000.1|ARO:3003950|msbA	26.5	563	587	582	6.94e-61	211
k141_79841_12	NCBI|WP_289811734.1|1|1|tetA(60)|tetA(60)||2|TETRACYCLINE|TETRACYCLINE|tetracycline_efflux_ABC_transporter_Tet(60)_subunit_A|AMR|tetracycline	31.3	467	587	579	2.43e-60	209
k141_79841_12	NCBI|WP_289811733.1|1|1|tetB(60)|tetB(60)||2|TETRACYCLINE|TETRACYCLINE|tetracycline_efflux_ABC_transporter_Tet(60)_subunit_B|AMR|tetracycline	26.4	583	587	579	4.51e-58	203
k141_79841_12	SARG|gb|ANZ79241.1|ARO:3004036|tetB(60)	26.8	583	587	579	3.18e-57	201
k141_79841_12	SARG|gi|505420018|ref|WP_015607120.1|	30.0	476	587	603	8.58e-55	194
k141_79841_12	SARG|gi|695842130|ref|WP_032755430.1|	30.0	476	587	603	1.18e-54	194
k141_79841_12	SARG|gi|648667297|ref|WP_026359044.1|	28.8	538	587	605	3.21e-54	193
k141_79841_24	SARG|gb|WP_104671188.1|ARO:3003948|efrA	28.7	237	244	575	1.09e-16	77.8
k141_79841_24	ResF|poxtA-Ef_1_WP094899500.1_1	24.8	218	244	538	2.02e-09	56.2
k141_79841_24	megares|MEG_8639|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|POXT_1	24.8	218	244	543	2.03e-09	56.2
k141_79841_24	NCBI|WP_094899500.1|1|1|poxtA-Ef|poxtA-Ef|target_protection|2|CHLORAMPHENICOL/FLORFENICOL/LINEZOLID|OXAZOLIDINONE/PHENICOL|ABC-F_type_ribosomal_protection_protein_PoxtA-Ef|AMR|multidrug	24.8	218	244	543	2.03e-09	56.2
k141_79841_24	SARG|gi|951389844|ref|WP_057765492.1|	28.3	191	244	492	4.74e-09	55.1
k141_79841_24	SARG|gi|517204321|ref|WP_018393139.1|	27.7	173	244	492	2.18e-07	50.1
k141_79841_24	SARG|AJ579365.gene.p01	27.2	173	244	492	2.92e-07	49.7
k141_79841_24	SARG|gi|738121094|ref|WP_036079133.1|	25.7	175	244	493	3.92e-07	49.3
k141_79841_24	SARG|gi|924348018|ref|WP_053483923.1|	24.5	204	244	492	1.26e-06	47.8
k141_79841_24	SARG|gi|817536927|ref|WP_046586836.1|	25.4	173	244	492	1.26e-06	47.8
k141_87045_22	CARD|gb|CYF42523.1|ARO:3004047|kdpD	28.8	664	663	885	3.98e-85	285
k141_87045_22	NCBI|WP_023042297.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	31.4	229	663	381	2.01e-19	89.7
k141_87045_22	megares|MEG_7509|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	31.4	229	663	381	2.01e-19	89.7
k141_87045_22	megares|MEG_7507|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	31.4	229	663	381	3.61e-19	89.0
k141_87045_22	NCBI|WP_063856738.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	31.4	229	663	381	3.61e-19	89.0
k141_87045_22	NCBI|WP_063856732.1|1|1|vanS-G|vanS-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-G|AMR|glycopeptide	25.3	300	663	367	4.18e-19	88.6
k141_87045_22	NCBI|WP_021418927.1|1|1|vanS-G|vanS-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-G|AMR|glycopeptide	27.5	255	663	368	5.67e-19	88.2
k141_87045_22	NCBI|WP_028530133.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	29.9	214	663	381	6.48e-19	88.2
k141_87045_22	megares|MEG_7506|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	29.9	214	663	381	6.48e-19	88.2
k141_87045_22	CARD|gb|ADM92606.1|ARO:3000549|adeS	28.7	216	663	361	7.04e-19	87.8
k141_87045_28	NCBI|WP_011029105.1|1|1|vanR-Sc|vanR-Sc|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-Sc|AMR|glycopeptide	35.7	210	216	231	3.70e-40	136
k141_87045_28	NCBI|WP_063856729.1|1|1|vanR-O|vanR-O|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-O|AMR|glycopeptide	34.9	215	216	233	3.90e-40	136
k141_87045_28	CARD|gb|ATC67679.1|ARO:3000838|arlR	36.9	198	216	219	5.23e-37	127
k141_87045_28	NCBI|WP_063856723.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	34.3	213	216	219	3.23e-35	123
k141_87045_28	NCBI|WP_002317273.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	33.8	213	216	219	1.28e-34	121
k141_87045_28	NCBI|WP_063856719.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	33.8	213	216	220	1.31e-34	121
k141_87045_28	NCBI|WP_032489743.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	33.8	213	216	220	1.84e-34	121
k141_87045_28	SARG|ZP_02848503	34.9	212	216	221	3.76e-34	120
k141_87045_28	NCBI|WP_002368697.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	33.8	213	216	220	2.03e-33	118
k141_87045_28	megares|MEG_4290|Drugs|beta-lactam|Mutant_porin_proteins|OMPR_1	34.7	222	216	252	1.66e-28	106
k141_87045_29	SARG|gb|AAG05187.1|ARO:3005067|ParS	30.6	235	391	428	5.21e-28	113
k141_87045_29	CARD|gb|ADM92606.1|ARO:3000549|adeS	28.6	231	391	361	3.01e-22	95.9
k141_87045_29	megares|MEG_7514|Drugs|Glycopeptide|VanL-type_regulator|VANSL_1	27.7	235	391	364	7.78e-20	89.0
k141_87045_29	NCBI|WP_063856745.1|1|1|vanS-L|vanS-L|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-L|AMR|glycopeptide	27.7	235	391	364	7.78e-20	89.0
k141_87045_29	NCBI|WP_222891058.1|1|1|vanS-P|vanS-P|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-P|AMR|glycopeptide	28.2	202	391	359	1.85e-19	87.8
k141_87045_29	megares|MEG_7521|Drugs|Glycopeptide|VanN-type_regulator|VANSN_1	27.0	233	391	364	1.94e-19	87.8
k141_87045_29	NCBI|WP_063856749.1|1|1|vanS-N|vanS-N|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-N|AMR|glycopeptide	27.0	233	391	364	1.94e-19	87.8
k141_101204_6	SARG|gi|446048013|ref|WP_000125868.1|	29.6	223	514	648	2.34e-24	105
k141_101204_6	SARG|gb|AYV52072.1|ARO:3002882|lmrD	27.8	230	514	664	2.33e-14	74.7
k141_101204_22	SARG|gi|447195835|ref|WP_001273091.1|	42.9	212	370	306	3.92e-45	156
k141_101204_22	SARG|ZP_04081918	42.5	212	370	306	1.08e-44	155
k141_101204_22	SARG|gi|447195836|ref|WP_001273092.1|	42.5	212	370	306	1.08e-44	155
k141_101204_22	SARG|gi|542061059|gb|ERI11611.1|	41.0	222	370	316	2.71e-44	154
k141_101204_22	SARG|gi|500194536|ref|WP_011867743.1|	40.1	222	370	306	5.83e-44	153
k141_101204_22	SARG|P42332	40.1	222	370	306	8.16e-44	152
k141_101204_22	megares|MEG_1213|Drugs|Bacitracin|Bacitracin_ABC_transporter|BCRA_1	40.1	222	370	306	8.16e-44	152
k141_101204_22	SARG|gi|510143239|gb|AGN36970.1|	40.1	222	370	313	9.70e-44	152
k141_101204_22	SARG|ABB80128	40.1	222	370	306	1.14e-43	152
k141_101204_22	SARG|gi|507044560|ref|WP_016115614.1|	38.7	222	370	306	1.14e-43	152
k141_72880_8	SARG|ZP_04679156	22.9	389	453	451	5.07e-31	123
k141_72880_12	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	28.5	123	693	231	7.72e-08	52.8
k141_72880_12	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	32.5	114	693	232	7.80e-08	52.8
k141_72880_17	SARG|gi|542061059|gb|ERI11611.1|	31.2	247	344	316	7.38e-21	90.5
k141_72880_17	NCBI|WP_002389535.1|1|1|bcrA_Lm|bcrA_Lm||2|peptide|peptide|peptide_resistance_ABC_transporter_ATP-binding_subunit_BcrA|AMR|peptide	28.3	244	344	307	3.15e-20	88.6
k141_72880_17	NCBI|QHA94808.1|1|1|narA|narA||1|MADURAMICIN/NARASIN/SALINOMYCIN|IONOPHORE|ionophore_ABC_transporter_ATP-binding_subunit_NarA|AMR|ionophore	23.5	281	344	293	1.38e-15	75.1
k141_72880_17	SARG|gb|AET10444.1|ARO:3004032|tetA(46)	27.8	245	344	574	4.54e-14	72.0
k141_72880_17	SARG|gb|AAK76137.1|ARO:3000024|patA	28.6	224	344	564	1.46e-11	64.3
k141_72880_17	megares|MEG_4318|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	25.4	228	344	655	3.53e-08	53.9
k141_72880_17	megares|MEG_4308|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	25.4	228	344	655	3.53e-08	53.9
k141_72880_17	SARG|gb|CDO61516.1|ARO:3003949|efrB	27.1	210	344	362	1.36e-07	51.6
k141_72880_17	megares|MEG_4316|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	25.0	228	344	655	2.56e-07	51.2
k141_72880_17	megares|MEG_4313|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	25.0	228	344	655	3.40e-07	50.8
k141_72880_18	SARG|gb|AET10444.1|ARO:3004032|tetA(46)	26.5	234	334	574	1.33e-12	67.4
k141_108323_4	SARG|gb|AAV85982.1|ARO:3000535|macB	31.8	233	352	644	6.16e-23	99.0
k141_108323_4	SARG|gi|696368937|ref|WP_032943949.1|	32.5	231	352	648	6.19e-23	99.0
k141_108323_4	SARG|gi|851913025|ref|WP_048215946.1|	32.5	231	352	648	6.19e-23	99.0
k141_108323_4	SARG|YP_002850060	32.5	231	352	648	6.19e-23	99.0
k141_108323_4	SARG|gi|489930965|ref|WP_003834285.1|	32.5	231	352	648	6.19e-23	99.0
k141_108323_4	SARG|gi|696361545|ref|WP_032936694.1|	32.5	231	352	648	8.34e-23	98.6
k141_108323_4	SARG|gi|489936909|ref|WP_003840216.1|	32.5	231	352	648	8.34e-23	98.6
k141_108323_4	SARG|gi|507079862|ref|WP_016150620.1|	32.5	231	352	648	8.34e-23	98.6
k141_108323_4	SARG|gi|949791377|ref|WP_057104572.1|	32.5	231	352	648	8.34e-23	98.6
k141_108323_4	SARG|gi|936194420|ref|WP_054528571.1|	32.5	231	352	648	1.51e-22	97.8
k141_108323_25	CARD|gb|AFK13828.1|ARO:3000823|ramA	32.0	103	200	124	3.27e-12	60.1
k141_108323_29	SARG|gb|WP_104671188.1|ARO:3003948|efrA	53.0	164	206	575	1.41e-53	179
k141_108323_29	SARG|gb|AYV52072.1|ARO:3002882|lmrD	37.3	244	206	664	1.50e-45	158
k141_108323_29	SARG|gb|AAK76137.1|ARO:3000024|patA	47.9	163	206	564	5.35e-45	155
k141_108323_29	SARG|gi|943909899|ref|WP_055545300.1|	49.4	164	206	601	5.77e-44	153
k141_108323_29	SARG|gi|1011969930|ref|WP_062776015.1|	49.4	164	206	601	5.77e-44	153
k141_108323_29	SARG|gi|655401130|ref|WP_028800283.1|	48.8	164	206	599	7.83e-44	153
k141_108323_29	SARG|gi|943896259|ref|WP_055534530.1|	46.7	169	206	601	1.11e-43	152
k141_108323_29	SARG|gi|860594225|ref|WP_048475168.1|	49.1	169	206	620	1.83e-43	152
k141_108323_29	SARG|gi|944470764|ref|WP_055701183.1|	48.2	168	206	601	2.12e-43	152
k141_108323_29	SARG|AF170880.4.gene1.p01	48.2	164	206	615	3.36e-43	151
k141_108323_34	NCBI|XSG12260.1|1|1|drcA|drcA||1|||daptomycin_efflux_ABC_transporter_ATP-binding_protein_DrcA|AMR|peptide	30.7	228	236	255	3.57e-31	114
k141_108323_34	SARG|gb|AAK76137.1|ARO:3000024|patA	27.5	207	236	564	3.06e-16	76.3
k141_108323_34	SARG|gb|WP_104671188.1|ARO:3003948|efrA	29.0	210	236	575	4.17e-16	75.9
k141_108323_34	SARG|gi|943909899|ref|WP_055545300.1|	27.9	226	236	601	3.22e-13	67.4
k141_108323_34	SARG|gi|1045390184|ref|WP_065479071.1|	27.8	209	236	605	4.35e-13	67.0
k141_108323_34	SARG|gi|662754041|ref|WP_030125200.1|	26.9	219	236	601	5.87e-13	66.6
k141_108323_34	SARG|gi|664100597|ref|WP_030638327.1|	26.9	219	236	601	5.87e-13	66.6
k141_108323_34	SARG|gi|505389066|ref|WP_015576168.1|	26.9	219	236	601	5.87e-13	66.6
k141_108323_34	SARG|gi|503923650|ref|WP_014157644.1|	26.9	219	236	601	5.87e-13	66.6
k141_108323_34	SARG|gi|764446018|ref|WP_044369325.1|	27.8	209	236	605	7.94e-13	66.2
k141_108323_35	SARG|gi|542061059|gb|ERI11611.1|	28.9	235	263	316	5.31e-18	80.9
k141_108323_35	NCBI|WP_002389535.1|1|1|bcrA_Lm|bcrA_Lm||2|peptide|peptide|peptide_resistance_ABC_transporter_ATP-binding_subunit_BcrA|AMR|peptide	26.1	238	263	307	3.69e-13	67.0
k141_108323_43	SARG|ZP_04081918	42.2	211	215	306	7.60e-48	158
k141_108323_43	SARG|gi|447195836|ref|WP_001273092.1|	42.2	211	215	306	1.07e-47	157
k141_108323_43	SARG|gi|447195835|ref|WP_001273091.1|	42.2	211	215	306	1.51e-47	157
k141_108323_43	SARG|gi|507044560|ref|WP_016115614.1|	42.2	211	215	306	1.51e-47	157
k141_108323_43	SARG|gi|445996719|ref|WP_000074574.1|	41.1	207	215	309	1.80e-46	154
k141_108323_43	SARG|YP_001373621	41.5	207	215	318	2.25e-46	154
k141_108323_43	SARG|gi|446026113|ref|WP_000103968.1|	41.7	211	215	306	2.36e-46	154
k141_108323_43	SARG|gi|500448961|gb|EOP61695.1|	41.3	213	215	306	3.33e-46	154
k141_108323_43	SARG|gi|500194536|ref|WP_011867743.1|	42.2	211	215	306	6.62e-46	153
k141_108323_43	SARG|P42332	41.7	211	215	306	9.32e-46	152
k141_108323_49	SARG|gb|AAK76136.1|ARO:3000025|patB	34.9	585	618	588	1.84e-107	335
k141_108323_49	SARG|gb|CDO61516.1|ARO:3003949|efrB	51.5	326	618	362	5.27e-107	326
k141_108323_49	SARG|gb|AYV52072.1|ARO:3002882|lmrD	35.7	515	618	664	2.50e-98	313
k141_108323_49	SARG|gi|496018010|ref|WP_008742581.1|	32.7	603	618	623	2.48e-87	283
k141_108323_49	SARG|gi|497748188|ref|WP_010062372.1|	31.9	589	618	605	6.16e-87	281
k141_108323_49	SARG|gi|948137056|ref|WP_056795395.1|	32.1	579	618	602	8.46e-86	278
k141_108323_49	SARG|gi|926351744|ref|WP_053683383.1|	32.2	594	618	648	4.89e-85	278
k141_108323_49	SARG|gb|ANZ79241.1|ARO:3004036|tetB(60)	32.5	588	618	579	5.08e-85	276
k141_108323_49	NCBI|WP_289811733.1|1|1|tetB(60)|tetB(60)||2|TETRACYCLINE|TETRACYCLINE|tetracycline_efflux_ABC_transporter_Tet(60)_subunit_B|AMR|tetracycline	31.6	589	618	579	9.96e-85	275
k141_108323_49	SARG|gi|664458452|ref|WP_030980047.1|	32.6	583	618	601	1.70e-84	275
k141_108323_50	SARG|gb|WP_104671188.1|ARO:3003948|efrA	44.9	526	774	575	6.37e-137	416
k141_108323_50	SARG|gb|AAK76137.1|ARO:3000024|patA	37.7	494	774	564	1.41e-107	339
k141_108323_50	SARG|gi|1011969930|ref|WP_062776015.1|	36.8	359	774	601	2.54e-66	230
k141_108323_50	SARG|gi|1045390184|ref|WP_065479071.1|	31.8	516	774	605	1.00e-65	228
k141_108323_50	SARG|gi|1033217078|gb|OAR27197.1|	30.8	507	774	601	4.63e-65	226
k141_108323_50	SARG|gi|928900436|ref|WP_053931243.1|	31.0	516	774	600	1.19e-64	225
k141_108323_50	SARG|gi|664579989|ref|WP_031094015.1|	31.0	516	774	601	1.22e-64	225
k141_108323_50	SARG|AF170880.4.gene1.p01	31.6	507	774	615	1.61e-64	225
k141_108323_50	SARG|gi|558888514|ref|WP_023543283.1|	31.4	507	774	615	1.61e-64	225
k141_108323_50	SARG|gi|944470764|ref|WP_055701183.1|	31.4	507	774	601	2.32e-64	224
k141_108323_68	SARG|gb|AYV52072.1|ARO:3002882|lmrD	34.2	506	596	664	8.95e-95	303
k141_108323_68	SARG|gi|944152509|ref|WP_055644808.1|	32.8	585	596	616	2.39e-92	295
k141_108323_68	SARG|gi|947982677|ref|WP_056642336.1|	32.6	602	596	626	4.29e-92	295
k141_108323_68	SARG|gi|639892676|ref|WP_024755698.1|	32.6	585	596	631	9.53e-92	294
k141_108323_68	SARG|gi|663350985|ref|WP_030349761.1|	32.5	576	596	613	1.69e-91	293
k141_108323_68	SARG|gi|917229923|ref|WP_051836635.1|	32.2	583	596	620	2.81e-91	293
k141_108323_68	SARG|gi|817122037|ref|WP_046494699.1|	31.9	576	596	613	6.52e-91	291
k141_108323_68	SARG|gi|1033217078|gb|OAR27197.1|	31.7	581	596	601	9.50e-91	291
k141_108323_68	SARG|gb|AAK76136.1|ARO:3000025|patB	31.3	581	596	588	9.60e-91	290
k141_108323_68	SARG|gi|558888514|ref|WP_023543283.1|	33.0	584	596	615	9.60e-91	291
k141_108323_69	SARG|gb|AAC74000.1|ARO:3003950|msbA	33.5	528	596	582	4.37e-85	275
k141_108323_69	SARG|gb|WP_104671188.1|ARO:3003948|efrA	31.6	497	596	575	2.33e-81	265
k141_108323_69	SARG|gb|AET10444.1|ARO:3004032|tetA(46)	30.9	469	596	574	2.54e-69	233
k141_108323_69	NCBI|WP_289811733.1|1|1|tetB(60)|tetB(60)||2|TETRACYCLINE|TETRACYCLINE|tetracycline_efflux_ABC_transporter_Tet(60)_subunit_B|AMR|tetracycline	31.9	504	596	579	2.10e-67	228
k141_108323_69	SARG|gi|493394434|ref|WP_006350564.1|	28.5	492	596	602	2.42e-67	229
k141_108323_69	SARG|gi|695865802|ref|WP_032778631.1|	28.7	492	596	605	3.58e-67	228
k141_108323_69	SARG|gb|ANZ79240.1|ARO:3004035|tetA(60)	29.1	578	596	579	4.07e-67	228
k141_108323_69	SARG|gb|ANZ79241.1|ARO:3004036|tetB(60)	31.8	500	596	579	4.07e-67	228
k141_108323_69	SARG|gi|497748188|ref|WP_010062372.1|	28.5	492	596	605	4.98e-67	228
k141_108323_69	SARG|gi|1045390184|ref|WP_065479071.1|	29.6	493	596	605	6.93e-67	228
k141_108323_74	megares|MEG_7514|Drugs|Glycopeptide|VanL-type_regulator|VANSL_1	26.4	242	1059	364	2.75e-16	80.9
k141_108323_74	NCBI|WP_063856745.1|1|1|vanS-L|vanS-L|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-L|AMR|glycopeptide	26.4	242	1059	364	2.75e-16	80.9
k141_108323_74	CARD|gb|AAG06465.1|ARO:3005063|cprR	34.5	119	1059	223	2.99e-10	60.5
k141_108323_74	CARD|gb|ATC67679.1|ARO:3000838|arlR	30.2	116	1059	219	2.29e-09	57.8
k141_108323_74	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	28.4	116	1059	231	1.61e-08	55.5
k141_108323_74	NCBI|WP_222891058.1|1|1|vanS-P|vanS-P|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-P|AMR|glycopeptide	20.4	226	1059	359	3.24e-08	55.8
k141_46504_12	megares|MEG_5396|Drugs|Aminocoumarins|Aminocoumarin-resistant_DNA_topoisomerases|PARY_1	44.1	681	644	703	2.14e-174	512
k141_54236_10	NCBI|WP_289811733.1|1|1|tetB(60)|tetB(60)||2|TETRACYCLINE|TETRACYCLINE|tetracycline_efflux_ABC_transporter_Tet(60)_subunit_B|AMR|tetracycline	32.1	582	633	579	6.43e-93	297
k141_54236_10	SARG|gb|ANZ79241.1|ARO:3004036|tetB(60)	32.8	586	633	579	3.97e-90	290
k141_54236_10	SARG|gb|AET10445.1|ARO:3004033|tetB(46)	32.9	516	633	578	1.17e-81	267
k141_54236_10	SARG|gb|WP_104671188.1|ARO:3003948|efrA	29.1	578	633	575	1.08e-71	241
k141_54236_10	SARG|gb|AAC74000.1|ARO:3003950|msbA	27.7	588	633	582	1.31e-68	233
k141_54236_10	SARG|gb|AYV52072.1|ARO:3002882|lmrD	30.6	490	633	664	6.47e-66	227
k141_54236_10	SARG|gb|AAK76136.1|ARO:3000025|patB	35.9	384	633	588	4.00e-65	223
k141_54236_10	SARG|gi|860594225|ref|WP_048475168.1|	27.2	574	633	620	1.04e-64	223
k141_54236_10	SARG|gi|926351744|ref|WP_053683383.1|	27.2	574	633	648	4.64e-64	222
k141_54236_10	SARG|gb|AAK76137.1|ARO:3000024|patA	28.3	548	633	564	6.51e-64	219
k141_54236_11	SARG|gb|AET10444.1|ARO:3004032|tetA(46)	29.1	564	591	574	5.34e-74	246
k141_54236_11	SARG|gb|WP_104671188.1|ARO:3003948|efrA	30.9	540	591	575	3.16e-70	236
k141_54236_11	SARG|gb|AAC74000.1|ARO:3003950|msbA	30.0	493	591	582	5.49e-65	222
k141_54236_11	SARG|gb|AAK76137.1|ARO:3000024|patA	30.9	501	591	564	3.83e-62	214
k141_54236_11	SARG|gi|1045390184|ref|WP_065479071.1|	28.1	487	591	605	4.27e-60	209
k141_54236_11	SARG|gi|662129758|ref|WP_030081404.1|	28.1	487	591	605	3.01e-59	207
k141_54236_11	SARG|gi|695865802|ref|WP_032778631.1|	28.1	487	591	605	4.17e-59	206
k141_54236_11	SARG|gi|764446018|ref|WP_044369325.1|	27.9	487	591	605	1.11e-58	205
k141_54236_11	SARG|gi|664180077|ref|WP_030714054.1|	27.9	487	591	605	2.12e-58	204
k141_54236_11	SARG|gi|928900436|ref|WP_053931243.1|	28.2	489	591	600	2.69e-58	204
k141_54236_12	NCBI|WP_005480402.1|1|1|tet(35)|tet(35)|efflux|2|TETRACYCLINE|TETRACYCLINE|tetracycline_efflux_Na+/H+_antiporter_family_transporter_Tet(35)|AMR|tetracycline	39.5	522	509	533	1.35e-96	301
k141_54236_12	SARG|AF353562.gene.p01	35.5	372	509	369	5.24e-54	185
k141_108923_18	SARG|HE999704.1.gene3064.p01	27.6	199	454	241	2.26e-16	77.4
k141_108923_18	SARG|gi|441475675|emb|CCQ25429.1|	27.7	141	454	211	5.02e-13	67.0
k141_108923_18	SARG|gi|555139174|gb|ESM81938.1|	21.8	380	454	453	1.46e-12	68.2
k141_108923_23	CARD|gb|ANK04027.1|ARO:3003838|gadW	40.3	67	508	242	1.39e-07	51.6
k141_108923_23	CARD|gb|AAC75429.1|ARO:3000833|evgS	28.4	102	508	1197	7.50e-06	47.8
k141_108923_57	SARG|gb|WP_104671188.1|ARO:3003948|efrA	25.8	570	590	575	2.64e-44	165
k141_108923_57	SARG|gi|926351744|ref|WP_053683383.1|	26.3	543	590	648	3.20e-38	148
k141_108923_57	SARG|gi|496018010|ref|WP_008742581.1|	26.8	544	590	623	1.61e-37	146
k141_108923_57	SARG|gi|490068471|ref|WP_003970646.1|	25.4	551	590	603	4.56e-37	144
k141_108923_57	SARG|gi|497748188|ref|WP_010062372.1|	25.2	551	590	605	6.28e-37	144
k141_108923_57	SARG|gi|664170108|ref|WP_030704355.1|	25.4	551	590	603	8.36e-37	144
k141_108923_57	SARG|gi|501350226|ref|WP_012381861.1|	25.4	551	590	603	8.36e-37	144
k141_108923_57	SARG|gi|827013130|ref|WP_047175495.1|	24.8	545	590	603	2.80e-36	142
k141_108923_57	SARG|gi|764446018|ref|WP_044369325.1|	24.8	545	590	605	2.85e-36	142
k141_108923_57	SARG|gi|1045390184|ref|WP_065479071.1|	24.9	551	590	605	5.20e-36	141
k141_73640_1	megares|MEG_7514|Drugs|Glycopeptide|VanL-type_regulator|VANSL_1	25.6	242	471	364	2.49e-15	76.3
k141_73640_1	NCBI|WP_063856745.1|1|1|vanS-L|vanS-L|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-L|AMR|glycopeptide	25.6	242	471	364	2.49e-15	76.3
k141_73640_1	NCBI|WP_222891058.1|1|1|vanS-P|vanS-P|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-P|AMR|glycopeptide	22.0	232	471	359	4.51e-13	69.3
k141_73640_1	CARD|gb|AEX49906.1|ARO:3003583|basS	24.3	247	471	477	8.82e-11	62.8
k141_18476_17	SARG|gi|1016275448|gb|AMX06027.1|	38.8	224	228	646	5.54e-40	144
k141_18476_17	SARG|gi|779956086|ref|WP_045403603.1|	38.8	224	228	646	7.63e-40	143
k141_18476_17	SARG|gi|779866095|ref|WP_045354445.1|	38.3	222	228	646	1.05e-39	143
k141_18476_17	SARG|gi|981224618|ref|WP_059445588.1|	38.8	224	228	646	1.05e-39	143
k141_18476_17	SARG|gi|836585048|ref|WP_047742322.1|	38.8	224	228	646	1.05e-39	143
k141_18476_17	SARG|gi|556301718|ref|WP_023292894.1|	38.3	230	228	646	1.44e-39	142
k141_18476_17	SARG|gi|695731723|ref|WP_032658224.1|	38.4	224	228	646	2.73e-39	142
k141_18476_17	SARG|gi|1016942913|ref|WP_063144441.1|	38.4	224	228	646	2.73e-39	142
k141_18476_17	SARG|gi|1028212610|ref|WP_063955653.1|	38.4	224	228	646	2.73e-39	142
k141_18476_17	SARG|gi|835749851|ref|WP_047648187.1|	38.4	224	228	646	2.73e-39	142
k141_102347_2	SARG|gi|670466162|ref|WP_031414939.1|	41.9	86	193	206	3.32e-12	61.6
k141_102347_2	SARG|gi|515720450|ref|WP_017153050.1|	45.8	72	193	210	6.70e-12	60.8
k141_102347_2	SARG|gi|1028848471|ref|WP_064017434.1|	39.7	73	193	206	3.20e-11	58.9
k141_102347_2	SARG|AF155139.2.gene5.p01	43.1	72	193	206	3.02e-10	56.2
k141_102347_2	NCBI|WP_063856927.1|1|1|vanZ-Pt|vanZ-Pt|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_protein_VanZ-Pt|AMR|glycopeptide	30.0	70	193	159	2.38e-06	44.7
k141_102347_19	SARG|gb|APB03219.1|ARO:3003986|TaeA	47.4	643	605	648	1.54e-201	578
k141_102347_19	megares|MEG_4309|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	30.1	518	605	655	7.68e-63	218
k141_102347_19	megares|MEG_4306|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	30.1	518	605	655	7.68e-63	218
k141_102347_19	megares|MEG_4313|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	29.9	518	605	655	2.82e-62	216
k141_102347_19	megares|MEG_4307|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	30.3	518	605	655	2.82e-62	216
k141_102347_19	megares|MEG_4312|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	29.9	518	605	655	2.82e-62	216
k141_102347_19	megares|MEG_4315|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	29.9	518	605	655	2.82e-62	216
k141_102347_19	megares|MEG_4304|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	29.9	518	605	655	2.82e-62	216
k141_102347_19	SARG|gb|AKA86814|ARO:3003746|optrA	29.9	518	605	655	2.82e-62	216
k141_102347_19	megares|MEG_4318|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	29.9	518	605	655	3.90e-62	216
k141_102347_35	NCBI|CCA59315.1|1|1|helR|helR||1|rifamycin|rifamycin|RNA_polymerase_recycling_motor_ATPase_HelR|AMR|rifamycin	23.3	313	1108	722	1.71e-16	83.6
k141_102347_37	NCBI|WP_420354091.1|1|1|blaDHA-37|blaDHA|hydrolase|2|CEPHALOSPORIN|beta-lactam|class_C_beta-lactamase_DHA-37|AMR|beta-lactam	26.6	233	393	379	1.07e-12	67.8
k141_102347_37	SARG|gb|AIT76105.1|ARO:3002147|DHA-16	26.2	233	393	379	3.42e-12	66.2
k141_102347_37	NCBI|WP_283624015.1|1|1|blaDHA-30|blaDHA|hydrolase|2|CEPHALOSPORIN|beta-lactam|class_C_beta-lactamase_DHA-30|AMR|beta-lactam	26.2	233	393	379	3.42e-12	66.2
k141_102347_37	SARG|HG798963.1.gene1.p01	26.1	226	393	379	8.15e-12	65.1
k141_102347_37	SARG|gb|AIT76094.1|ARO:3002149|DHA-18	26.5	226	393	379	1.45e-11	64.3
k141_102347_37	NCBI|WP_024474547.1|1|1|blaDHA-32|blaDHA|hydrolase|2|CEPHALOSPORIN|beta-lactam|class_C_beta-lactamase_DHA-32|AMR|beta-lactam	26.5	226	393	379	1.45e-11	64.3
k141_102347_37	SARG|gb|WP_128268236.1|ARO:3006469|DHA-28	26.1	226	393	379	1.45e-11	64.3
k141_102347_37	NCBI|WP_311033305.1|1|1|blaDHA-31|blaDHA|hydrolase|2|CEPHALOSPORIN|beta-lactam|class_C_beta-lactamase_DHA-31|AMR|beta-lactam	26.5	226	393	379	1.45e-11	64.3
k141_102347_37	SARG|gb|WP_109545067.1|ARO:3006468|DHA-27	26.5	226	393	379	1.94e-11	63.9
k141_102347_37	NCBI|WP_420354090.1|1|1|blaDHA-36|blaDHA|hydrolase|2|CEPHALOSPORIN|beta-lactam|class_C_beta-lactamase_DHA-36|AMR|beta-lactam	25.2	246	393	379	1.94e-11	63.9
k141_32014_7	NCBI|XSG12260.1|1|1|drcA|drcA||1|||daptomycin_efflux_ABC_transporter_ATP-binding_protein_DrcA|AMR|peptide	31.4	204	295	255	4.86e-27	105
k141_32014_7	SARG|ABB80128	29.3	232	295	306	3.45e-26	103
k141_32014_7	SARG|P42332	28.9	232	295	306	3.41e-25	101
k141_32014_7	megares|MEG_1213|Drugs|Bacitracin|Bacitracin_ABC_transporter|BCRA_1	28.9	232	295	306	3.41e-25	101
k141_32014_7	SARG|gi|510143239|gb|AGN36970.1|	28.9	232	295	313	3.82e-25	101
k141_32014_7	SARG|AAD21213	28.4	232	295	306	2.41e-24	99.0
k141_32014_7	NCBI|WP_289811733.1|1|1|tetB(60)|tetB(60)||2|TETRACYCLINE|TETRACYCLINE|tetracycline_efflux_ABC_transporter_Tet(60)_subunit_B|AMR|tetracycline	28.1	231	295	579	1.59e-22	96.3
k141_32014_7	SARG|gb|AAC74000.1|ARO:3003950|msbA	31.3	249	295	582	1.79e-21	93.2
k141_32014_7	SARG|gi|953808775|ref|WP_058042812.1|	30.0	247	295	608	3.38e-21	92.4
k141_32014_7	SARG|gi|702897513|ref|WP_033300957.1|	29.8	235	295	601	8.28e-21	91.3
k141_32014_8	SARG|gi|981224618|ref|WP_059445588.1|	32.6	218	296	646	9.47e-28	111
k141_32014_8	SARG|gi|498115003|ref|WP_010429159.1|	32.7	211	296	646	1.29e-27	111
k141_32014_8	SARG|gi|998245120|ref|WP_061098715.1|	32.2	211	296	646	4.35e-27	109
k141_32014_8	SARG|gi|836585048|ref|WP_047742322.1|	32.7	211	296	646	4.35e-27	109
k141_32014_8	SARG|gi|695748190|ref|WP_032674455.1|	32.2	211	296	646	1.09e-26	108
k141_32014_8	SARG|gi|779866095|ref|WP_045354445.1|	32.2	211	296	646	1.09e-26	108
k141_32014_8	SARG|gi|544824889|ref|WP_021240890.1|	32.2	211	296	646	1.09e-26	108
k141_32014_8	SARG|gi|779956086|ref|WP_045403603.1|	32.2	211	296	646	1.09e-26	108
k141_32014_8	SARG|gi|695731723|ref|WP_032658224.1|	32.2	211	296	646	1.09e-26	108
k141_32014_8	SARG|gi|851931792|ref|WP_048222288.1|	32.2	211	296	646	1.09e-26	108
k141_32014_52	CARD|gb|WKR28567.1|ARO:3007678|IreK	33.5	671	756	718	2.03e-84	281
k141_32014_54	SARG|gb|BAD63613.1|ARO:3002816|clbC	33.5	340	347	350	1.71e-54	181
k141_32014_54	NCBI|WP_032491462.1|1|1|cfr|cfr|target_modification|2|CHLORAMPHENICOL/CLINDAMYCIN/FLORFENICOL/LINEZOLID/STREPTOGRAMIN_B/TIAMULIN/VIRGINIAMYCIN|LINCOSAMIDE/OXAZOLIDINONE/PHENICOL/PLEUROMUTILIN/STREPTOGRAMIN|23S_rRNA_(adenine(2503)-C(8))-methyltransferase_Cfr|AMR|multidrug	34.2	330	347	349	1.62e-50	171
k141_32014_54	SARG|AJ249217.gene.p01	34.2	330	347	349	4.48e-50	169
k141_32014_57	SARG|gi|851935911|ref|WP_048224705.1|	32.3	322	324	660	6.07e-45	161
k141_32014_57	SARG|gi|1002399350|ref|WP_061382108.1|	32.3	322	324	660	6.07e-45	161
k141_32014_57	SARG|gi|757799830|ref|WP_043017032.1|	32.0	322	324	660	8.36e-45	160
k141_32014_57	SARG|gi|851917461|ref|WP_048217311.1|	31.7	322	324	660	3.01e-44	159
k141_32014_57	SARG|gi|489117806|ref|WP_003027650.1|	31.7	322	324	660	3.01e-44	159
k141_32014_57	SARG|gi|696375142|ref|WP_032949690.1|	31.7	322	324	660	3.01e-44	159
k141_32014_57	SARG|gi|851981245|ref|WP_048240645.1|	31.7	322	324	660	3.01e-44	159
k141_32014_57	SARG|gi|765458296|ref|WP_044714032.1|	31.7	322	324	660	4.15e-44	159
k141_32014_57	SARG|B1LLK9	31.7	322	324	660	1.08e-43	157
k141_32014_57	SARG|gi|507079934|ref|WP_016150692.1|	31.4	322	324	660	2.05e-43	157
k141_32014_66	SARG|gi|851913025|ref|WP_048215946.1|	37.6	234	253	648	6.50e-40	144
k141_32014_66	SARG|gi|489930965|ref|WP_003834285.1|	37.6	234	253	648	6.50e-40	144
k141_32014_66	SARG|gi|696368937|ref|WP_032943949.1|	37.9	232	253	648	8.94e-40	144
k141_32014_66	SARG|gi|489936909|ref|WP_003840216.1|	37.6	234	253	648	8.94e-40	144
k141_32014_66	SARG|gi|507079862|ref|WP_016150620.1|	37.6	234	253	648	8.94e-40	144
k141_32014_66	SARG|gi|949791377|ref|WP_057104572.1|	37.6	234	253	648	8.94e-40	144
k141_32014_66	SARG|gi|936194420|ref|WP_054528571.1|	37.6	234	253	648	1.23e-39	144
k141_32014_66	SARG|YP_002850060	37.6	234	253	648	1.23e-39	144
k141_32014_66	SARG|gi|696361545|ref|WP_032936694.1|	37.9	232	253	648	1.23e-39	144
k141_32014_66	SARG|gi|491270241|ref|WP_005128370.1|	37.2	234	253	648	3.20e-39	142
k141_32014_69	SARG|gb|ABA71733.1|ARO:3002972|vanTG	40.0	370	375	712	1.03e-77	252
k141_32014_69	SARG|gb|ABX54690.1|ARO:3002974|vanTrL	38.0	371	375	366	1.40e-73	232
k141_32014_69	NCBI|CZR78671.1|1|1|vanT-Cd|vanT-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|membrane-bound_serine_racemase_VanT-Cd|AMR|glycopeptide	37.2	376	375	712	1.37e-69	230
k141_32014_69	NCBI|WP_063856752.1|1|1|vanT-G|vanT-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|membrane-bound_serine_racemase_VanT-G|AMR|glycopeptide	37.3	370	375	711	5.46e-65	218
k141_32014_69	NCBI|WP_063856755.1|1|1|vanT-C|vanT-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|membrane-bound_serine_racemase_VanT-C|AMR|glycopeptide	38.1	362	375	700	4.68e-64	215
k141_32014_69	SARG|AAY67970	34.5	371	375	698	3.29e-63	213
k141_32014_69	SARG|AF162694.1.gene4.p01	34.5	371	375	698	4.58e-63	213
k141_32014_69	SARG|gi|657686198|ref|WP_029487032.1|	34.5	371	375	698	4.58e-63	213
k141_32014_69	NCBI|WP_063856756.1|1|1|vanT-C|vanT-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|membrane-bound_serine_racemase_VanT-C|AMR|glycopeptide	37.6	375	375	700	6.56e-63	212
k141_32014_69	NCBI|WP_063856759.1|1|1|vanTc3|vanTc3|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|membrane-bound_serine_racemase_VanT|AMR|glycopeptide	37.2	371	375	700	4.74e-62	210
k141_55488_1	megares|MEG_7501|Drugs|Glycopeptide|VanC-type_regulator|VANSC_1	25.8	236	397	354	1.38e-19	88.2
k141_55488_1	megares|MEG_7500|Drugs|Glycopeptide|VanC-type_regulator|VANSC_1	25.8	236	397	352	1.53e-18	85.1
k141_55488_1	megares|MEG_7503|Drugs|Glycopeptide|VanC-type_regulator|VANSC_1	25.0	236	397	354	2.85e-18	84.3
k141_55488_1	megares|MEG_7497|Drugs|Glycopeptide|VanC-type_regulator|VANSC_1	25.8	236	397	376	3.43e-18	84.3
k141_55488_1	NCBI|WP_034869172.1|1|1|vanS-C|vanS-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-C|AMR|glycopeptide	25.8	236	397	376	3.43e-18	84.3
k141_55488_1	megares|MEG_7502|Drugs|Glycopeptide|VanC-type_regulator|VANSC_1	25.0	236	397	361	1.01e-17	82.8
k141_55488_1	NCBI|WP_063856733.1|1|1|vanS-C|vanS-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-C|AMR|glycopeptide	25.0	236	397	361	1.01e-17	82.8
k141_55488_1	NCBI|WP_063856743.1|1|1|vanS-C|vanS-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-C|AMR|glycopeptide	25.0	236	397	361	1.36e-17	82.4
k141_55488_1	megares|MEG_7499|Drugs|Glycopeptide|VanC-type_regulator|VANSC_1	25.0	236	397	361	1.36e-17	82.4
k141_55488_1	megares|MEG_7514|Drugs|Glycopeptide|VanL-type_regulator|VANSL_1	27.4	241	397	364	1.39e-17	82.4
k141_55488_3	CARD|gb|AAC75429.1|ARO:3000833|evgS	28.5	467	615	1197	3.01e-43	166
k141_55488_3	megares|MEG_7514|Drugs|Glycopeptide|VanL-type_regulator|VANSL_1	26.4	239	615	364	1.74e-14	74.3
k141_55488_3	NCBI|WP_063856745.1|1|1|vanS-L|vanS-L|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-L|AMR|glycopeptide	26.4	239	615	364	1.74e-14	74.3
k141_55488_3	NCBI|WP_222891058.1|1|1|vanS-P|vanS-P|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-P|AMR|glycopeptide	24.9	237	615	359	9.50e-14	72.0
k141_55488_3	CARD|gb|ADM92605.1|ARO:3000553|adeR	36.1	119	615	247	5.97e-12	65.1
k141_55488_3	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	30.8	107	615	231	1.40e-09	57.8
k141_55488_3	CARD|gb|AEX49906.1|ARO:3003583|basS	25.7	245	615	477	1.63e-08	56.2
k141_55488_3	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	28.0	107	615	232	2.19e-07	51.2
k141_55488_9	megares|MEG_1992|Drugs|beta-lactam|Class_C_betalactamases|CMY_1	30.9	123	297	291	2.10e-10	59.3
k141_55488_9	CARD|gb|CAA79966.1|ARO:3003665|NmcR	31.1	132	297	295	1.36e-08	53.9
k141_55488_10	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	35.7	70	109	232	5.46e-07	45.1
k141_47944_24	CARD|gb|BAD59497.1|ARO:3000501|rpoB2	53.5	1229	1266	1162	0.0	1216
k141_47944_24	CARD|gb|WP_041777404.1|ARO:3004480|Bado_rpoB_RIF	52.4	1226	1266	1186	0.0	1156
k141_47944_24	megares|MEG_8674|Drugs|Rifampin|Rifampin-resistant_beta-subunit_of_RNA_polymerase_RpoB|RPOB_1	52.4	1226	1266	1186	0.0	1156
k141_47944_47	SARG|gi|488374619|ref|WP_002444004.1|	20.2	446	459	452	8.52e-19	87.4
k141_47944_57	NCBI|WP_063856734.1|1|1|vanS-E|vanS-E|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-E|AMR|glycopeptide	31.3	265	587	357	2.49e-25	106
k141_47944_57	megares|MEG_7511|Drugs|Glycopeptide|VanE-type_regulator|VANSE_1	31.3	265	587	357	2.49e-25	106
k141_47944_57	NCBI|WP_006285582.1|1|1|vanS-F|vanS-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-F|AMR|glycopeptide	26.5	309	587	365	2.19e-21	95.1
k141_47944_57	NCBI|WP_011461302.1|1|1|vanS-I|vanS-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-I|AMR|glycopeptide	29.5	241	587	392	3.10e-20	92.0
k141_47944_57	NCBI|AXB64455.1|1|1|vanS-Cd|vanS-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|VanG-Cd-type_glycopeptide_resistance_histidine_kinase_VanS|AMR|glycopeptide	31.6	234	587	380	2.23e-18	86.3
k141_47944_57	megares|MEG_7498|Drugs|Glycopeptide|VanC-type_regulator|VANSC_1	31.6	234	587	380	2.23e-18	86.3
k141_47944_57	megares|MEG_7500|Drugs|Glycopeptide|VanC-type_regulator|VANSC_1	29.7	232	587	352	5.46e-18	84.7
k141_47944_57	megares|MEG_7503|Drugs|Glycopeptide|VanC-type_regulator|VANSC_1	28.7	254	587	354	7.49e-18	84.3
k141_47944_57	NCBI|WP_063856742.1|1|1|vanS-Pt|vanS-Pt|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-Pt|AMR|glycopeptide	28.3	251	587	388	7.69e-18	84.7
k141_47944_57	megares|MEG_7489|Drugs|Glycopeptide|VanA-type_regulator|VANSA_1	28.3	251	587	388	7.69e-18	84.7
k141_47944_58	megares|MEG_7449|Drugs|Glycopeptide|VanA-type_regulator|VANRA_1	47.2	229	238	231	2.66e-68	209
k141_47944_58	NCBI|WP_063856716.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	47.2	229	238	231	2.66e-68	209
k141_47944_58	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	46.1	230	238	232	5.52e-68	208
k141_47944_58	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	46.1	230	238	232	5.52e-68	208
k141_47944_58	NCBI|WP_222891057.1|1|1|vanR-P|vanR-P|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-P|AMR|glycopeptide	46.8	235	238	239	1.58e-66	204
k141_47944_58	NCBI|AXB64454.1|1|1|vanR-Cd|vanR-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G-Cd|AMR|glycopeptide	45.9	233	238	233	2.63e-66	204
k141_47944_58	NCBI|WP_021418928.1|1|1|vanR-G|vanR-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G|AMR|glycopeptide	44.2	231	238	235	6.41e-65	200
k141_47944_58	NCBI|WP_063856721.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	45.7	230	238	231	8.02e-65	200
k141_47944_58	NCBI|WP_063856718.1|1|1|vanR-E|vanR-E|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-E|AMR|glycopeptide	44.3	228	238	229	1.51e-64	199
k141_47944_58	NCBI|WP_001280781.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	44.5	229	238	231	3.23e-64	198
k141_47944_66	SARG|gb|APB03214.1|ARO:3003980|tetA(48)	35.6	222	242	343	4.03e-40	140
k141_47944_66	SARG|YP_001373621	35.0	223	242	318	2.52e-39	137
k141_47944_66	SARG|gi|542061059|gb|ERI11611.1|	34.5	223	242	316	4.75e-39	136
k141_47944_66	SARG|gb|AAA26793|ARO:3003748|oleC	31.3	217	242	325	1.93e-35	127
k141_47944_66	megares|MEG_4276|Drugs|MLS|MLS_resistance_ABC_efflux_pumps|OLEC_1	31.3	217	242	325	1.93e-35	127
k141_47944_66	megares|MEG_4383|Drugs|Tetracycline|Tetracycline_resistance_ABC_efflux_pumps|OTRC_1	27.4	230	242	351	2.79e-19	84.3
k141_47944_66	SARG|gb|AAR96051.1|ARO:3002894|otrC	27.4	230	242	351	5.26e-19	83.6
k141_47944_76	SARG|gi|943909899|ref|WP_055545300.1|	26.9	551	597	601	2.18e-44	166
k141_47944_76	SARG|gi|917203192|ref|WP_051809904.1|	27.1	550	597	620	1.77e-43	163
k141_47944_76	SARG|gi|926351744|ref|WP_053683383.1|	27.1	553	597	648	3.23e-43	163
k141_47944_76	SARG|gi|772774655|ref|WP_045322518.1|	27.6	548	597	620	4.47e-43	162
k141_47944_76	SARG|gi|917229923|ref|WP_051836635.1|	28.4	552	597	620	6.09e-43	162
k141_47944_76	SARG|gi|1033217078|gb|OAR27197.1|	27.3	550	597	601	9.14e-43	161
k141_47944_76	SARG|gi|799286378|ref|WP_045936958.1|	27.8	550	597	620	1.13e-42	161
k141_47944_76	SARG|gi|926294973|ref|WP_053631154.1|	27.8	550	597	620	1.13e-42	161
k141_47944_76	SARG|gi|928900436|ref|WP_053931243.1|	27.8	557	597	600	1.23e-42	160
k141_47944_76	SARG|gi|664579989|ref|WP_031094015.1|	27.8	557	597	601	1.25e-42	160
k141_47944_88	NCBI|XSG12260.1|1|1|drcA|drcA||1|||daptomycin_efflux_ABC_transporter_ATP-binding_protein_DrcA|AMR|peptide	29.0	272	560	255	2.82e-27	109
k141_47944_88	SARG|gi|936194420|ref|WP_054528571.1|	32.6	242	560	648	3.31e-24	105
k141_47944_88	SARG|gi|696368937|ref|WP_032943949.1|	32.2	242	560	648	2.44e-23	103
k141_47944_88	SARG|gi|851913025|ref|WP_048215946.1|	32.2	242	560	648	2.44e-23	103
k141_47944_88	SARG|gi|489930965|ref|WP_003834285.1|	32.2	242	560	648	2.44e-23	103
k141_47944_88	SARG|YP_002850060	32.2	242	560	648	3.25e-23	102
k141_47944_88	SARG|gi|851922185|ref|WP_048218206.1|	32.2	242	560	648	4.32e-23	102
k141_47944_88	SARG|gi|949718947|ref|WP_057063453.1|	32.2	242	560	648	4.32e-23	102
k141_47944_88	SARG|gi|696375069|ref|WP_032949617.1|	32.2	242	560	648	4.32e-23	102
k141_47944_88	SARG|gi|696361545|ref|WP_032936694.1|	32.2	242	560	648	4.32e-23	102
k141_47944_94	SARG|DQ018711.1.gene4.p01	28.2	284	345	322	9.72e-31	117
k141_47944_94	SARG|gi|738848198|ref|WP_036737307.1|	28.8	285	345	323	2.65e-30	116
k141_47944_94	NCBI|WP_063856705.1|1|1|vanH-D|vanH-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|D-lactate_dehydrogenase_VanH-D|AMR|glycopeptide	29.3	273	345	323	7.07e-30	115
k141_47944_94	SARG|gi|737310392|ref|WP_035293250.1|	28.1	285	345	323	1.88e-29	114
k141_47944_94	SARG|gb|MBY8651254.1|ARO:3007188|vanH_in_vanP_cl	29.6	260	345	314	3.07e-29	113
k141_47944_94	SARG|gi|552942232|ref|WP_023043160.1|	28.1	274	345	323	3.62e-29	113
k141_47944_94	SARG|gi|740152780|ref|WP_037997109.1|	28.8	285	345	322	1.82e-28	111
k141_47944_94	SARG|AY082011.1.gene6.p01	27.7	274	345	323	2.56e-28	111
k141_47944_103	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	23.8	105	532	228	3.31e-06	47.4
k141_47944_103	CARD|gb|BAB36671.1|ARO:3000832|evgA	25.9	81	532	204	3.50e-06	47.0
k141_47944_105	CARD|gb|AFK13828.1|ARO:3000823|ramA	30.2	96	294	124	2.82e-11	58.9
k141_61864_18	NCBI|BAB64566.1|1|1|bexA|bexA|efflux|1|EFFLUX|EFFLUX|multidrug_efflux_MATE_transporter_BexA|AMR|efflux	21.4	355	463	443	1.16e-15	77.8
k141_61864_18	SARG|BAA31456	24.5	420	463	456	2.89e-15	76.6
k141_26684_16	NCBI|WP_000163435.1|1|1|mupA|mupA|insensitivity|2|mupirocin|mupirocin|mupirocin-resistant_isoleucine--tRNA_ligase_MupA|AMR|mupirocin	23.5	693	802	1024	4.56e-32	133
k141_26684_16	SARG|gb|CAA53189|ARO:3000521|mupA	23.5	693	802	1024	4.56e-32	133
k141_26684_16	megares|MEG_4089|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPA_1	23.5	677	802	1024	7.97e-32	132
k141_26684_16	megares|MEG_4090|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPA_1	23.5	677	802	1024	7.97e-32	132
k141_26684_16	megares|MEG_4091|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPB_1	22.8	690	802	1033	1.40e-31	131
k141_26684_16	SARG|gb|AEY83581|ARO:3000510|mupB	22.8	690	802	1033	1.40e-31	131
k141_26684_16	megares|MEG_3295|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|ILES_1	21.4	887	802	1107	1.03e-16	84.0
k141_26684_16	SARG|gb|ADP36409.1|ARO:3003730|Bifidobacteria	21.4	887	802	1107	1.03e-16	84.0
k141_26684_47	NCBI|XSG12260.1|1|1|drcA|drcA||1|||daptomycin_efflux_ABC_transporter_ATP-binding_protein_DrcA|AMR|peptide	38.8	227	248	255	1.54e-41	141
k141_26684_47	SARG|gi|495736522|ref|WP_008461101.1|	37.2	226	248	648	1.05e-39	144
k141_26684_47	SARG|gi|823326845|ref|WP_047080664.1|	36.3	226	248	648	1.13e-36	135
k141_26684_47	SARG|gi|695793471|ref|WP_032707680.1|	36.3	226	248	648	1.13e-36	135
k141_26684_47	SARG|gi|823302270|ref|WP_047057473.1|	36.3	226	248	648	1.13e-36	135
k141_26684_47	SARG|gi|976146774|ref|WP_059305359.1|	36.3	226	248	648	1.13e-36	135
k141_26684_47	SARG|gi|1022664304|ref|WP_063420886.1|	36.3	226	248	648	1.13e-36	135
k141_26684_47	SARG|gi|895981299|ref|WP_049056431.1|	36.3	226	248	648	1.13e-36	135
k141_26684_47	SARG|gi|823309640|ref|WP_047064288.1|	36.3	226	248	648	1.13e-36	135
k141_26684_47	SARG|gi|823281237|ref|WP_047037467.1|	36.3	226	248	648	1.13e-36	135
k141_26684_51	SARG|HE999704.1.gene3064.p01	28.8	212	434	241	9.46e-16	75.5
k141_26684_51	SARG|gi|441475675|emb|CCQ25429.1|	31.1	148	434	211	7.18e-12	63.5
k141_26684_62	SARG|DQ212986.1.gene3.p01	67.7	62	72	75	2.56e-24	85.5
k141_26684_79	SARG|gi|928900436|ref|WP_053931243.1|	26.4	535	577	600	7.25e-39	149
k141_26684_79	SARG|gi|664579989|ref|WP_031094015.1|	26.4	535	577	601	7.32e-39	149
k141_26684_79	SARG|gi|917229923|ref|WP_051836635.1|	24.5	576	577	620	1.83e-37	145
k141_26684_79	SARG|gi|558888514|ref|WP_023543283.1|	26.0	572	577	615	5.90e-37	144
k141_26684_79	SARG|gi|917172177|ref|WP_051778889.1|	24.8	568	577	620	8.31e-37	144
k141_26684_79	SARG|gi|516795764|ref|WP_018105258.1|	25.9	541	577	601	9.61e-37	143
k141_26684_79	SARG|gi|917155568|ref|WP_051762280.1|	24.8	568	577	620	1.52e-36	143
k141_26684_79	SARG|gi|917166849|ref|WP_051773561.1|	24.8	568	577	620	1.52e-36	143
k141_26684_79	SARG|gi|517347347|ref|WP_018522839.1|	25.7	541	577	601	1.76e-36	142
k141_26684_79	SARG|gi|919568551|ref|WP_052871170.1|	24.6	568	577	620	2.06e-36	142
k141_26684_80	SARG|gb|AAK76136.1|ARO:3000025|patB	27.4	497	545	588	4.04e-48	175
k141_26684_80	SARG|gb|AYV52072.1|ARO:3002882|lmrD	23.9	464	545	664	1.48e-38	149
k141_26684_80	SARG|gb|AAK76137.1|ARO:3000024|patA	24.3	515	545	564	4.84e-28	117
k141_26684_155	SARG|gi|488374619|ref|WP_002444004.1|	25.4	452	462	452	6.10e-29	117
k141_26684_155	SARG|gb|CAE00499.1|ARO:3003835|cdeA	22.2	418	462	441	2.51e-26	109
k141_26684_158	SARG|gi|1022688710|ref|WP_063443532.1|	37.0	227	248	648	1.05e-39	144
k141_26684_158	SARG|gi|823326845|ref|WP_047080664.1|	36.6	227	248	648	1.99e-39	143
k141_26684_158	SARG|gi|695793471|ref|WP_032707680.1|	36.6	227	248	648	2.74e-39	142
k141_26684_158	SARG|gi|823291602|ref|WP_047047573.1|	36.6	227	248	648	2.74e-39	142
k141_26684_158	SARG|gi|895981299|ref|WP_049056431.1|	36.6	227	248	648	2.74e-39	142
k141_26684_158	SARG|gi|823281237|ref|WP_047037467.1|	36.6	227	248	648	2.74e-39	142
k141_26684_158	SARG|gi|895967513|ref|WP_049046752.1|	36.6	227	248	648	2.74e-39	142
k141_26684_158	SARG|gi|779903733|ref|WP_045374054.1|	36.6	227	248	648	2.74e-39	142
k141_26684_158	SARG|gi|823302270|ref|WP_047057473.1|	36.6	227	248	648	3.77e-39	142
k141_26684_158	SARG|gi|976146774|ref|WP_059305359.1|	36.6	227	248	648	3.77e-39	142
k141_26684_165	SARG|gb|AAK76136.1|ARO:3000025|patB	28.2	216	251	588	1.16e-14	72.0
k141_26684_165	SARG|gb|AYV52072.1|ARO:3002882|lmrD	27.5	244	251	664	4.03e-14	70.5
k141_26684_165	SARG|gi|748767925|ref|WP_040019608.1|	27.0	230	251	623	1.42e-12	65.9
k141_26684_165	SARG|gi|662754041|ref|WP_030125200.1|	27.4	248	251	601	3.43e-12	64.7
k141_26684_165	SARG|gi|664100597|ref|WP_030638327.1|	27.4	248	251	601	3.43e-12	64.7
k141_26684_165	SARG|gi|505389066|ref|WP_015576168.1|	27.4	248	251	601	3.43e-12	64.7
k141_26684_165	SARG|gi|503923650|ref|WP_014157644.1|	27.4	248	251	601	3.43e-12	64.7
k141_26684_165	SARG|AF170880.4.gene1.p01	27.3	242	251	615	3.46e-12	64.7
k141_26684_165	SARG|gi|558888514|ref|WP_023543283.1|	27.3	242	251	615	3.46e-12	64.7
k141_26684_165	SARG|gi|926400371|ref|WP_053728483.1|	27.9	233	251	603	6.24e-12	63.9
k141_26684_187	megares|MEG_6058|Drugs|MLS|23S_rRNA_methyltransferases|RLMH_1	59.7	159	160	159	2.33e-62	188
k141_26684_191	SARG|B2VGJ3	29.9	278	289	273	3.21e-26	103
k141_26684_191	SARG|Q1LSL8	27.9	280	289	275	3.34e-26	103
k141_26684_191	SARG|YP_001436495	28.7	282	289	272	1.18e-24	99.0
k141_26684_191	SARG|Q6D159	29.3	280	289	272	4.41e-24	97.4
k141_26684_191	SARG|YP_002236533	29.1	285	289	273	4.49e-24	97.4
k141_26684_191	SARG|ZP_03833009	28.9	280	289	272	6.12e-24	97.1
k141_26684_191	SARG|ZP_03945515	26.8	310	289	291	8.51e-24	97.1
k141_26684_191	SARG|YP_001455939	29.7	286	289	272	1.63e-23	95.9
k141_26684_191	SARG|YP_002931998	28.2	287	289	272	2.27e-23	95.5
k141_26684_191	SARG|ZP_03829223	28.6	280	289	272	2.27e-23	95.5
k141_26684_197	megares|MEG_4316|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	37.9	525	642	655	3.19e-118	365
k141_26684_197	megares|MEG_4304|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	37.9	525	642	655	8.89e-118	364
k141_26684_197	SARG|gb|AKA86814|ARO:3003746|optrA	37.9	525	642	655	8.89e-118	364
k141_26684_197	megares|MEG_4323|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	37.9	525	642	655	1.25e-117	364
k141_26684_197	megares|MEG_4321|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	37.9	525	642	655	1.76e-117	363
k141_26684_197	megares|MEG_4317|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	37.9	525	642	655	1.76e-117	363
k141_26684_197	megares|MEG_4322|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	38.1	525	642	655	1.76e-117	363
k141_26684_197	megares|MEG_4314|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	37.9	525	642	655	1.76e-117	363
k141_26684_197	megares|MEG_4309|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	38.1	525	642	655	1.76e-117	363
k141_26684_197	megares|MEG_4319|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	37.9	525	642	655	1.76e-117	363
k141_26684_208	NCBI|WP_002294513.1|1|1|lsa(E)|lsa(E)|target_protection|2|LINCOSAMIDE/STREPTOGRAMIN|LINCOSAMIDE/STREPTOGRAMIN|ABC-F_type_ribosomal_protection_protein_Lsa(E)|AMR|multidrug	51.9	526	527	494	8.17e-176	503
k141_26684_208	SARG|gi|922777287|ref|WP_053374995.1|	49.0	526	527	492	1.40e-168	485
k141_26684_208	SARG|gi|1032346815|ref|WP_064200323.1|	49.2	526	527	492	7.99e-168	483
k141_26684_208	SARG|gi|1043542993|ref|WP_065386235.1|	48.7	526	527	492	1.60e-167	482
k141_26684_208	SARG|gi|950274036|ref|WP_057309929.1|	48.5	526	527	492	3.22e-167	481
k141_26684_208	SARG|gi|763097172|ref|WP_043977684.1|	47.9	526	527	492	4.56e-167	481
k141_26684_208	SARG|gi|944535691|ref|WP_055747198.1|	49.2	526	527	492	6.46e-167	481
k141_26684_208	SARG|gi|506326044|ref|WP_015845803.1|	48.5	526	527	492	1.30e-166	480
k141_26684_208	SARG|gi|1003765182|ref|WP_061463312.1|	48.5	526	527	492	2.60e-166	479
k141_26684_208	SARG|gi|550167391|ref|WP_022586684.1|	48.1	526	527	492	2.60e-166	479
k141_103555_45	NCBI|AKA30736.1|1|1|cxpE|cxpE||1|CHLORAMPHENICOL|PHENICOL|phenicol_efflux_transporter_CxpE|AMR|phenicol	24.1	216	470	397	2.94e-10	60.8
k141_103555_60	SARG|gi|921979807|ref|WP_053271336.1|	35.1	205	253	648	3.73e-29	114
k141_103555_60	SARG|gi|507050365|ref|WP_016121371.1|	29.7	222	253	309	5.11e-27	105
k141_103555_60	SARG|gi|488053456|ref|WP_002124853.1|	29.7	222	253	309	7.11e-27	104
k141_103555_60	SARG|gi|488120365|ref|WP_002191762.1|	29.7	222	253	309	9.90e-27	104
k141_103555_60	SARG|gi|488068784|ref|WP_002140181.1|	29.7	222	253	309	9.90e-27	104
k141_103555_60	SARG|gi|507023808|ref|WP_016095885.1|	29.3	222	253	309	1.38e-26	103
k141_103555_60	SARG|gi|488067981|ref|WP_002139378.1|	29.3	222	253	309	1.92e-26	103
k141_103555_60	SARG|gi|487936534|ref|WP_002010000.1|	29.3	222	253	309	1.92e-26	103
k141_103555_60	SARG|gi|507055561|ref|WP_016126482.1|	29.7	222	253	309	2.67e-26	103
k141_103555_60	SARG|gi|447057510|ref|WP_001134766.1|	29.0	221	253	309	2.67e-26	103
k141_103555_72	NCBI|WP_011906899.1|1|1|estDL136|estDL136||2|CHLORAMPHENICOL/FLORFENICOL|PHENICOL|phenicol_hydrolase|AMR|phenicol	36.7	278	331	308	7.08e-47	159
k141_103555_72	megares|MEG_2865|Drugs|Phenicol|Chloramphenicol_hydrolase|ESTD_1	38.5	231	331	310	1.30e-43	151
k141_103555_76	NCBI|WP_049581834.1|1|1|dfrA45|dfrA45|insensitivity|2|diaminopyrimidine|diaminopyrimidine|diaminopyrimidine-resistant_dihydrofolate_reductase_DfrA45|AMR|diaminopyrimidine	39.2	125	171	164	3.50e-27	99.4
k141_103555_76	megares|MEG_8062|Drugs|Trimethoprim|Dihydrofolate_reductase|DFRA_1	36.5	159	171	195	4.23e-26	97.4
k141_103555_76	SARG|gb|WP_000949574.1|ARO:3005348|DfrA36	36.5	159	171	195	4.23e-26	97.4
k141_103555_76	NCBI|WP_038694170.1|1|1|dfrA49|dfrA49|insensitivity|2|diaminopyrimidine|diaminopyrimidine|diaminopyrimidine-resistant_dihydrofolate_reductase_DfrA49|AMR|diaminopyrimidine	34.9	129	171	167	9.32e-25	93.2
k141_103555_76	SARG|gb|WP_197749399.1|ARO:3005349|DfrA38	37.7	130	171	166	1.56e-22	87.4
k141_103555_76	SARG|CAE53424	36.9	130	171	169	4.68e-22	86.3
k141_103555_76	SARG|gb|ASF80997.1|ARO:3005164|dfrA35	38.1	126	171	170	1.34e-21	85.1
k141_103555_76	NCBI|WP_012655890.1|1|1|dfrE|dfrE|insensitivity|2|diaminopyrimidine|diaminopyrimidine|diaminopyrimidine-resistant_dihydrofolate_reductase_DfrE|AMR|diaminopyrimidine	38.3	107	171	164	4.55e-21	83.6
k141_103555_76	SARG|gb|WP_149100971.1|ARO:3005351|DfrA39	31.3	160	171	165	3.92e-19	78.6
k141_103555_76	SARG|gi|771651285|ref|WP_045232968.1|	32.3	161	171	165	5.50e-19	78.2
k141_103555_89	SARG|gi|1035706844|ref|WP_064548272.1|	37.7	77	966	648	1.11e-07	54.7
k141_103555_91	megares|MEG_7169|Drugs|Tetracycline|Tetracycline_resistance_ribosomal_protection_proteins|TETO_1	28.0	432	605	629	1.32e-24	107
k141_103555_91	ResF|tet(O/W)_3_AM889120_1	28.0	432	605	639	1.36e-24	107
k141_103555_91	megares|MEG_7170|Drugs|Tetracycline|Tetracycline_resistance_ribosomal_protection_proteins|TETO_1	28.0	432	605	629	3.09e-24	106
k141_103555_91	ResF|tet(O/W)_4_AM889121_1	28.0	432	605	639	3.18e-24	106
k141_103555_91	SARG|CAE46078	26.5	438	605	639	4.23e-24	105
k141_103555_91	SARG|gi|1004359922|gb|AMP42228.1|	27.1	431	605	639	9.90e-24	104
k141_103555_91	SARG|P21598	26.3	438	605	639	9.90e-24	104
k141_103555_91	SARG|ABN79417	27.5	432	605	639	9.90e-24	104
k141_103555_91	SARG|gi|291587251|gb|ADE19326.1|	26.3	438	605	644	1.00e-23	104
k141_103555_91	megares|MEG_7163|Drugs|Tetracycline|Tetracycline_resistance_ribosomal_protection_proteins|TETO_1	27.9	437	605	629	1.28e-23	104
k141_20397_11	NCBI|WP_063856927.1|1|1|vanZ-Pt|vanZ-Pt|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_protein_VanZ-Pt|AMR|glycopeptide	39.4	104	159	159	1.46e-11	58.2
k141_20397_11	SARG|gi|515720450|ref|WP_017153050.1|	33.7	92	159	210	2.15e-10	55.8
k141_20397_11	SARG|AF155139.2.gene5.p01	41.3	63	159	206	3.94e-10	55.1
k141_20397_11	SARG|gi|1028848471|ref|WP_064017434.1|	42.9	63	159	206	3.94e-10	55.1
k141_20397_11	SARG|gi|670466162|ref|WP_031414939.1|	42.9	63	159	206	5.45e-10	54.7
k141_97864_26	SARG|gi|695273519|ref|WP_032495453.1|	31.6	187	291	245	3.73e-21	89.0
k141_97864_26	NCBI|WP_063844619.1|1|1|erm(B)|erm(B)|target_modification|2|CLINDAMYCIN/ERYTHROMYCIN/STREPTOGRAMIN_B|LINCOSAMIDE/MACROLIDE/STREPTOGRAMIN|23S_rRNA_(adenine(2058)-N(6))-methyltransferase_Erm(B)|AMR|multidrug	31.0	187	291	245	3.73e-21	89.0
k141_97864_26	SARG|gi|488250641|ref|WP_002321849.1|	31.6	187	291	245	5.17e-21	88.6
k141_97864_26	NCBI|WP_063844598.1|1|1|erm(B)|erm(B)|target_modification|2|CLINDAMYCIN/ERYTHROMYCIN/STREPTOGRAMIN_B|LINCOSAMIDE/MACROLIDE/STREPTOGRAMIN|23S_rRNA_(adenine(2058)-N(6))-methyltransferase_Erm(B)|AMR|multidrug	31.6	187	291	245	7.16e-21	88.2
k141_97864_26	megares|MEG_2801|Drugs|MLS|23S_rRNA_methyltransferases|ERMB_1	31.6	187	291	253	8.26e-21	88.2
k141_97864_26	NCBI|WP_001038790.1|1|1|erm(B)|erm(B)|target_modification|2|CLINDAMYCIN/ERYTHROMYCIN/STREPTOGRAMIN_B|LINCOSAMIDE/MACROLIDE/STREPTOGRAMIN|23S_rRNA_(adenine(2058)-N(6))-methyltransferase_Erm(B)|AMR|multidrug	31.6	187	291	245	9.92e-21	87.8
k141_97864_26	NCBI|WP_063844601.1|1|1|erm(B)|erm(B)|target_modification|2|CLINDAMYCIN/ERYTHROMYCIN/STREPTOGRAMIN_B|LINCOSAMIDE/MACROLIDE/STREPTOGRAMIN|23S_rRNA_(adenine(2058)-N(6))-methyltransferase_Erm(B)|AMR|multidrug	31.0	187	291	245	1.90e-20	87.0
k141_97864_26	SARG|AAL91930	31.0	187	291	245	2.63e-20	86.7
k141_97864_26	SARG|gi|494752321|ref|WP_007487729.1|	31.4	188	291	245	2.63e-20	86.7
k141_97864_26	NCBI|WP_063844614.1|1|1|erm(B)|erm(B)|target_modification|2|CLINDAMYCIN/ERYTHROMYCIN/STREPTOGRAMIN_B|LINCOSAMIDE/MACROLIDE/STREPTOGRAMIN|23S_rRNA_(adenine(2058)-N(6))-methyltransferase_Erm(B)|AMR|multidrug	31.0	187	291	245	2.63e-20	86.7
k141_97864_29	megares|MEG_4091|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPB_1	45.8	1012	1040	1033	0.0	944
k141_97864_29	SARG|gb|AEY83581|ARO:3000510|mupB	45.8	1012	1040	1033	0.0	944
k141_97864_29	NCBI|WP_000163435.1|1|1|mupA|mupA|insensitivity|2|mupirocin|mupirocin|mupirocin-resistant_isoleucine--tRNA_ligase_MupA|AMR|mupirocin	44.6	1035	1040	1024	0.0	936
k141_97864_29	megares|MEG_4089|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPA_1	44.6	1035	1040	1024	0.0	936
k141_97864_29	megares|MEG_4090|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPA_1	44.3	1035	1040	1024	0.0	929
k141_97864_29	SARG|gb|CAA53189|ARO:3000521|mupA	44.3	1035	1040	1024	0.0	929
k141_97864_29	megares|MEG_3295|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|ILES_1	37.2	1093	1040	1107	8.09e-229	680
k141_97864_29	SARG|gb|ADP36409.1|ARO:3003730|Bifidobacteria	37.2	1093	1040	1107	8.09e-229	680
k141_97864_42	megares|MEG_4308|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	43.8	630	655	655	4.98e-169	497
k141_97864_42	megares|MEG_4318|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	43.7	630	655	655	3.98e-168	494
k141_97864_42	megares|MEG_4307|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	43.7	630	655	655	7.95e-168	494
k141_97864_42	megares|MEG_4316|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	43.5	630	655	655	1.12e-167	493
k141_97864_42	megares|MEG_4304|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	43.5	630	655	655	2.24e-167	493
k141_97864_42	SARG|gb|AKA86814|ARO:3003746|optrA	43.5	630	655	655	2.24e-167	493
k141_97864_42	megares|MEG_4313|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	43.5	630	655	655	4.48e-167	492
k141_97864_42	megares|MEG_4312|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	43.5	630	655	655	6.34e-167	491
k141_97864_42	megares|MEG_4315|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	43.5	630	655	655	6.34e-167	491
k141_97864_42	megares|MEG_4322|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	43.3	628	655	655	1.27e-166	491
k141_97864_51	NCBI|WP_222891058.1|1|1|vanS-P|vanS-P|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-P|AMR|glycopeptide	29.3	225	686	359	3.83e-20	91.7
k141_97864_51	megares|MEG_7514|Drugs|Glycopeptide|VanL-type_regulator|VANSL_1	29.3	222	686	364	1.77e-19	89.7
k141_97864_51	NCBI|WP_063856745.1|1|1|vanS-L|vanS-L|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-L|AMR|glycopeptide	29.3	222	686	364	1.77e-19	89.7
k141_97864_51	CARD|gb|AEX49906.1|ARO:3003583|basS	26.8	235	686	477	3.76e-14	74.3
k141_97864_51	NCBI|XSG12258.1|1|1|drcS|drcS||1|||daptomycin_efflux_sensor_histidine_kinase_DrcS|AMR|peptide	23.5	260	686	341	2.36e-10	61.6
k141_97864_51	NCBI|WP_063856723.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	29.6	115	686	219	4.12e-10	59.3
k141_97864_51	NCBI|WP_002317273.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	29.6	115	686	219	4.12e-10	59.3
k141_97864_51	NCBI|WP_063856719.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	29.6	115	686	220	4.18e-10	59.3
k141_97864_51	NCBI|WP_032489743.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	29.6	115	686	220	7.62e-10	58.5
k141_97864_51	CARD|gb|AAG06465.1|ARO:3005063|cprR	31.4	121	686	223	4.77e-09	56.2
k141_111836_28	SARG|gb|AAC75314.1|ARO:3003578|pmrF	35.2	105	322	322	1.33e-09	57.4
k141_111836_35	SARG|gb|AAC75314.1|ARO:3003578|pmrF	34.4	93	316	322	3.25e-06	47.0
k141_111836_36	SARG|gb|AAC75314.1|ARO:3003578|pmrF	28.6	105	331	322	1.12e-06	48.5
k141_111836_52	SARG|gb|CAE00499.1|ARO:3003835|cdeA	40.7	435	451	441	4.41e-110	331
k141_111836_75	SARG|gb|ADZ12699.1|ARO:3005091|RanA	27.8	194	348	258	1.45e-19	85.9
k141_111836_75	SARG|gb|AAK76136.1|ARO:3000025|patB	26.3	213	348	588	8.57e-10	58.9
k141_111836_75	SARG|gb|AYV52072.1|ARO:3002882|lmrD	23.6	191	348	664	1.50e-07	52.0
k141_111836_75	SARG|gb|AET10445.1|ARO:3004033|tetB(46)	22.1	195	348	578	4.41e-07	50.4
k141_111836_75	SARG|gi|736993687|ref|WP_034989673.1|	63.6	33	348	513	2.28e-06	48.1
k141_111836_75	SARG|AF024666.2.gene6.p01	63.6	33	348	513	2.28e-06	48.1
k141_111836_75	SARG|gi|171851258|emb|CAQ04234.1|	60.6	33	348	483	5.17e-06	47.0
k141_111836_90	NCBI|WP_005480402.1|1|1|tet(35)|tet(35)|efflux|2|TETRACYCLINE|TETRACYCLINE|tetracycline_efflux_Na+/H+_antiporter_family_transporter_Tet(35)|AMR|tetracycline	25.4	504	466	533	4.72e-32	127
k141_111836_109	SARG|gi|505420018|ref|WP_015607120.1|	29.3	239	251	603	1.53e-22	95.1
k141_111836_109	SARG|gb|WP_104671188.1|ARO:3003948|efrA	31.0	216	251	575	5.02e-22	93.6
k141_111836_109	SARG|gi|817122037|ref|WP_046494699.1|	29.6	226	251	613	1.77e-21	92.0
k141_111836_109	SARG|gi|695842130|ref|WP_032755430.1|	28.9	239	251	603	2.37e-21	91.7
k141_111836_109	SARG|gi|748767925|ref|WP_040019608.1|	27.8	227	251	623	4.43e-21	90.9
k141_111836_109	SARG|gi|953808775|ref|WP_058042812.1|	29.7	219	251	608	5.93e-21	90.5
k141_111836_109	SARG|gi|948137056|ref|WP_056795395.1|	30.8	221	251	602	8.00e-21	90.1
k141_111836_109	SARG|gi|558888514|ref|WP_023543283.1|	28.4	225	251	615	1.48e-20	89.4
k141_111836_109	SARG|gi|739906046|ref|WP_037756452.1|	30.3	221	251	620	1.49e-20	89.4
k141_111836_109	SARG|gi|695865802|ref|WP_032778631.1|	28.9	239	251	605	2.00e-20	89.0
k141_111836_111	CARD|gb|ATC67679.1|ARO:3000838|arlR	41.7	223	224	219	5.28e-51	164
k141_111836_111	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	42.4	224	224	228	9.73e-51	163
k141_111836_111	NCBI|WP_002317273.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	39.5	220	224	219	3.06e-47	154
k141_111836_111	NCBI|WP_063856719.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	39.5	220	224	220	3.15e-47	154
k141_111836_111	NCBI|WP_032489743.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	39.5	220	224	220	4.45e-47	154
k141_111836_111	NCBI|WP_002368697.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	40.0	220	224	220	6.30e-47	153
k141_111836_111	NCBI|WP_063856723.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	39.1	220	224	219	2.44e-46	152
k141_111836_111	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	40.0	230	224	232	3.97e-45	149
k141_111836_111	megares|MEG_7449|Drugs|Glycopeptide|VanA-type_regulator|VANRA_1	39.3	229	224	231	5.45e-45	149
k141_111836_111	NCBI|WP_063856716.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	39.3	229	224	231	5.45e-45	149
k141_111836_112	CARD|gb|ABD30512.1|ARO:3000839|arlS	32.5	252	553	451	1.66e-27	114
k141_111836_112	CARD|gb|AEX49906.1|ARO:3003583|basS	33.8	219	553	477	4.86e-23	101
k141_111836_117	NCBI|QHA94808.1|1|1|narA|narA||1|MADURAMICIN/NARASIN/SALINOMYCIN|IONOPHORE|ionophore_ABC_transporter_ATP-binding_subunit_NarA|AMR|ionophore	28.4	218	233	293	2.38e-33	120
k141_111836_117	SARG|gi|542061059|gb|ERI11611.1|	28.1	242	233	316	1.31e-24	98.2
k141_111836_117	SARG|gi|446026113|ref|WP_000103968.1|	28.9	235	233	306	4.20e-24	96.7
k141_111836_117	SARG|gi|507044560|ref|WP_016115614.1|	29.0	238	233	306	4.19e-23	94.0
k141_111836_117	SARG|ZP_04081918	29.4	235	233	306	5.82e-23	93.6
k141_111836_117	SARG|gi|447195836|ref|WP_001273092.1|	29.4	235	233	306	8.08e-23	93.2
k141_111836_117	SARG|gi|447195835|ref|WP_001273091.1|	29.4	235	233	306	1.12e-22	92.8
k141_111836_117	SARG|P42332	30.9	217	233	306	4.15e-22	91.3
k141_111836_117	SARG|AAD21213	30.9	217	233	306	5.75e-22	90.9
k141_111836_117	SARG|gi|445996719|ref|WP_000074574.1|	28.5	235	233	309	5.99e-22	90.9
k141_111836_134	SARG|YP_002861121	38.3	81	207	212	1.87e-13	65.5
k141_111836_134	SARG|YP_001779894	37.0	81	207	212	1.80e-12	62.8
k141_111836_134	SARG|YP_001389621	37.0	81	207	212	1.80e-12	62.8
k141_111836_134	SARG|YP_001785579	35.0	80	207	212	2.35e-11	59.7
k141_111836_134	SARG|U19459.gene.p01	30.9	81	207	212	7.78e-10	55.5
k141_111836_134	NCBI|WP_031281281.1|1|1|catB|catB|acetyltransferase|2|CHLORAMPHENICOL|PHENICOL|type_B_phenicol_O-acetyltransferase|AMR|phenicol	26.5	136	207	210	1.43e-09	54.7
k141_111836_134	SARG|M58472.1.gene1.p01	29.2	113	207	209	1.94e-09	54.3
k141_111836_134	NCBI|WP_021018581.1|1|1|catB8|catB8|acetyltransferase|2|CHLORAMPHENICOL|PHENICOL|type_B-3_phenicol_O-acetyltransferase_CatB8|AMR|phenicol	26.7	135	207	210	2.69e-09	53.9
k141_111836_134	NCBI|WP_071846375.1|1|1|catB3|catB3|acetyltransferase|2|CHLORAMPHENICOL|PHENICOL|type_B-3_phenicol_O-acetyltransferase_CatB3|AMR|phenicol	29.1	117	207	210	2.69e-09	53.9
k141_111836_134	SARG|ABF20240	29.1	117	207	210	9.44e-09	52.4
k141_111836_138	megares|MEG_7543|Drugs|Glycopeptide|VanG-type_accessory_protein|VANWG_1	33.8	130	518	281	6.15e-14	71.2
k141_111836_138	megares|MEG_7544|Drugs|Glycopeptide|VanG-type_accessory_protein|VANWG_1	33.8	130	518	281	6.15e-14	71.2
k141_111836_138	NCBI|WP_063856762.1|1|1|vanW-G|vanW-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_accessory_protein_VanW-G|AMR|glycopeptide	33.8	130	518	281	6.15e-14	71.2
k141_111836_138	NCBI|WP_021419095.1|1|1|vanW-G|vanW-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_accessory_protein_VanW-G|AMR|glycopeptide	33.8	130	518	281	6.15e-14	71.2
k141_111836_142	CARD|gb|AAD51347.1|ARO:3003067|smeS	28.1	270	473	467	9.51e-30	120
k141_111836_142	CARD|gb|CYF42523.1|ARO:3004047|kdpD	27.0	222	473	885	6.20e-18	85.9
k141_111836_143	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	46.5	230	235	228	2.02e-66	204
k141_111836_143	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	43.4	226	235	231	1.40e-59	186
k141_111836_143	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	42.5	226	235	232	8.19e-59	184
k141_111836_143	CARD|gb|ATC67679.1|ARO:3000838|arlR	41.5	224	235	219	1.56e-58	183
k141_111836_143	CARD|gb|AAG05188.1|ARO:3005068|ParR	40.5	227	235	235	1.32e-55	176
k141_111836_143	CARD|gb|AAD51348.1|ARO:3003066|smeR	40.5	232	235	229	6.23e-55	174
k141_111836_143	NCBI|WP_021418928.1|1|1|vanR-G|vanR-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G|AMR|glycopeptide	40.1	232	235	235	5.97e-54	172
k141_111836_143	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	40.6	234	235	232	7.73e-54	172
k141_111836_143	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	40.6	234	235	232	7.73e-54	172
k141_111836_143	NCBI|WP_063856727.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	38.5	231	235	232	1.55e-53	171
k141_91149_4	NCBI|WP_222891058.1|1|1|vanS-P|vanS-P|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-P|AMR|glycopeptide	27.8	227	983	359	3.17e-22	98.6
k141_91149_4	CARD|gb|ADM92606.1|ARO:3000549|adeS	27.3	242	983	361	7.53e-17	82.4
k141_91149_4	CARD|gb|AAC75429.1|ARO:3000833|evgS	33.1	142	983	1197	7.95e-12	68.6
k141_91149_4	NCBI|WP_063856723.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	32.8	119	983	219	1.73e-11	63.9
k141_91149_4	NCBI|WP_002317273.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	32.8	119	983	219	1.73e-11	63.9
k141_91149_4	NCBI|WP_063856719.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	32.8	119	983	220	1.75e-11	63.9
k141_91149_4	NCBI|WP_032489743.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	32.8	119	983	220	2.37e-11	63.5
k141_91149_4	NCBI|WP_002368697.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	31.9	119	983	220	8.70e-10	58.9
k141_91149_4	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	30.6	121	983	232	1.03e-09	58.9
k141_91149_4	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	30.3	122	983	231	1.85e-09	58.2
k141_91149_18	SARG|gb|AAG05187.1|ARO:3005067|ParS	35.4	65	78	428	1.92e-08	48.1
k141_91149_19	megares|MEG_3448|Drugs|Aminoglycosides|Aminoglycoside_efflux_pumps|KDPE_1	43.2	227	234	225	1.40e-60	189
k141_91149_19	CARD|gb|AAC73788.1|ARO:3003841|kdpE	43.2	227	234	225	1.40e-60	189
k141_91149_19	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	36.8	228	234	231	4.76e-46	152
k141_91149_19	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	33.3	228	234	232	1.20e-40	138
k141_91149_19	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	33.3	228	234	232	1.20e-40	138
k141_91149_19	NCBI|WP_063856718.1|1|1|vanR-E|vanR-E|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-E|AMR|glycopeptide	31.0	226	234	229	2.20e-40	137
k141_91149_19	CARD|gb|ATC67679.1|ARO:3000838|arlR	36.2	224	234	219	2.37e-40	137
k141_91149_19	NCBI|WP_005228837.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	32.2	227	234	231	4.62e-40	136
k141_91149_19	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	34.3	230	234	232	4.75e-40	136
k141_91149_19	NCBI|WP_021418928.1|1|1|vanR-G|vanR-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G|AMR|glycopeptide	34.2	228	234	235	1.44e-39	135
k141_91149_42	NCBI|XSG12259.1|1|1|drcR|drcR||1|||daptomycin_efflux_response_regulator_transcription_factor_DrcR|AMR|peptide	48.9	221	224	223	7.66e-75	224
k141_91149_42	CARD|gb|AAD51348.1|ARO:3003066|smeR	32.9	219	224	229	3.78e-35	123
k141_91149_42	CARD|gb|ADM92605.1|ARO:3000553|adeR	33.6	223	224	247	5.42e-32	115
k141_91149_42	NCBI|AXB64454.1|1|1|vanR-Cd|vanR-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G-Cd|AMR|glycopeptide	30.7	228	224	233	1.08e-31	114
k141_91149_42	NCBI|WP_063856724.1|1|1|vanR-L|vanR-L|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-L|AMR|glycopeptide	31.9	226	224	231	1.12e-30	112
k141_91149_42	CARD|gb|AAG05188.1|ARO:3005068|ParR	28.6	220	224	235	1.53e-27	103
k141_91149_42	CARD|gb|SIP52035.1|ARO:3004054|Paer_CpxR	28.9	204	224	225	3.03e-23	92.4
k141_91149_42	megares|MEG_4290|Drugs|beta-lactam|Mutant_porin_proteins|OMPR_1	27.0	237	224	252	2.80e-20	85.1
k141_91149_43	NCBI|XSG12258.1|1|1|drcS|drcS||1|||daptomycin_efflux_sensor_histidine_kinase_DrcS|AMR|peptide	41.7	211	340	341	2.50e-48	164
k141_91149_44	NCBI|XSG12260.1|1|1|drcA|drcA||1|||daptomycin_efflux_ABC_transporter_ATP-binding_protein_DrcA|AMR|peptide	49.4	249	256	255	3.44e-84	251
k141_91149_44	SARG|gi|696361545|ref|WP_032936694.1|	39.0	251	256	648	7.48e-59	196
k141_91149_44	SARG|YP_002850060	40.7	221	256	648	1.04e-58	196
k141_91149_44	SARG|gi|696368937|ref|WP_032943949.1|	40.7	221	256	648	1.45e-58	195
k141_91149_44	SARG|gi|851913025|ref|WP_048215946.1|	40.7	221	256	648	1.45e-58	195
k141_91149_44	SARG|gi|489936909|ref|WP_003840216.1|	40.7	221	256	648	1.45e-58	195
k141_91149_44	SARG|gi|507079862|ref|WP_016150620.1|	40.7	221	256	648	1.45e-58	195
k141_91149_44	SARG|gi|949791377|ref|WP_057104572.1|	40.7	221	256	648	1.45e-58	195
k141_91149_44	SARG|gi|489930965|ref|WP_003834285.1|	40.7	221	256	648	1.45e-58	195
k141_91149_44	SARG|gi|922960663|ref|WP_053388845.1|	39.6	235	256	648	1.45e-58	195
k141_91149_45	NCBI|XSG12257.1|1|1|drcB|drcB||1|||daptomycin_efflux_ABC_transporter_permease_DrcB|AMR|peptide	27.8	691	667	641	5.04e-52	189
k141_91149_74	SARG|gi|851928815|ref|WP_048221086.1|	51.9	216	228	648	4.60e-76	240
k141_91149_74	SARG|gi|780033092|ref|WP_045444768.1|	51.9	216	228	648	4.60e-76	240
k141_91149_74	SARG|gi|922960663|ref|WP_053388845.1|	51.4	216	228	648	1.91e-74	236
k141_91149_74	SARG|gi|757799695|ref|WP_043016897.1|	51.4	216	228	648	2.68e-74	236
k141_91149_74	SARG|gi|1045891604|ref|WP_065554100.1|	51.4	216	228	648	2.68e-74	236
k141_91149_74	SARG|gi|507082903|ref|WP_016153652.1|	51.4	216	228	648	2.68e-74	236
k141_91149_74	SARG|gi|740856590|ref|WP_038641842.1|	51.4	216	228	648	2.68e-74	236
k141_91149_74	SARG|gi|507086196|ref|WP_016156937.1|	51.4	216	228	648	2.68e-74	236
k141_91149_74	SARG|gi|803568669|ref|WP_046077412.1|	50.5	220	228	648	5.27e-74	235
k141_91149_74	SARG|gi|446110352|ref|WP_000188207.1|	50.5	220	228	648	5.27e-74	235
k141_91149_76	SARG|gb|AAV85982.1|ARO:3000535|macB	35.1	419	417	644	2.09e-49	176
k141_91149_76	SARG|gi|1035670474|ref|WP_064517458.1|	31.8	424	417	648	4.47e-34	133
k141_91149_76	SARG|gi|1001720867|ref|WP_061274204.1|	31.5	419	417	648	4.47e-34	133
k141_91149_76	SARG|gi|1035717981|ref|WP_064557480.1|	31.8	424	417	648	4.47e-34	133
k141_91149_76	SARG|gi|495736522|ref|WP_008461101.1|	31.2	420	417	648	8.25e-34	132
k141_91149_76	SARG|gi|746243059|ref|WP_039291473.1|	31.2	420	417	648	8.25e-34	132
k141_91149_76	SARG|gi|746253210|ref|WP_039301529.1|	31.2	420	417	648	8.25e-34	132
k141_91149_76	SARG|gi|495067432|ref|WP_007792257.1|	29.9	421	417	647	2.05e-33	131
k141_91149_76	SARG|gi|1035706844|ref|WP_064548272.1|	30.5	420	417	648	2.06e-33	131
k141_91149_76	SARG|gi|736472622|ref|WP_034494292.1|	31.4	424	417	648	3.79e-33	130
k141_91149_86	SARG|L42544.gene.p01	30.7	638	913	651	1.30e-88	295
k141_91149_86	SARG|AAV80410	30.4	638	913	651	1.79e-87	291
k141_91149_86	SARG|YP_002850805	31.8	623	913	652	9.22e-85	284
k141_91149_86	SARG|ZP_02952732	31.2	618	913	652	1.74e-83	281
k141_91149_86	SARG|ZP_02632674	31.2	618	913	660	2.09e-83	281
k141_91149_86	SARG|L20800.gene.p01	31.2	618	913	652	3.34e-83	280
k141_91149_86	NCBI|WP_063856409.1|1|1|tet(Q)|tet(Q)|target_protection|2|TETRACYCLINE|TETRACYCLINE|tetracycline_resistance_ribosomal_protection_protein_Tet(Q)|AMR|tetracycline	30.5	609	913	641	1.69e-79	270
k141_91149_86	SARG|NP_348076	29.9	618	913	652	2.16e-79	270
k141_91149_86	SARG|AAZ79478	30.5	609	913	657	2.41e-79	270
k141_91149_86	SARG|Q08425	30.6	614	913	641	3.23e-79	269
k141_91149_104	NCBI|WP_002389535.1|1|1|bcrA_Lm|bcrA_Lm||2|peptide|peptide|peptide_resistance_ABC_transporter_ATP-binding_subunit_BcrA|AMR|peptide	28.4	204	444	307	8.91e-17	79.7
k141_91149_104	SARG|gi|779838942|ref|WP_045343641.1|	28.0	200	444	648	3.87e-16	79.7
k141_91149_104	SARG|gi|817602846|ref|WP_046596462.1|	27.0	200	444	648	3.87e-16	79.7
k141_91149_104	SARG|gi|959866458|ref|WP_058145168.1|	27.5	200	444	648	3.87e-16	79.7
k141_91149_104	SARG|gi|810369244|ref|WP_046334012.1|	27.5	200	444	647	5.13e-16	79.3
k141_91149_104	SARG|gi|555246906|ref|WP_023230855.1|	27.5	200	444	648	5.14e-16	79.3
k141_91149_104	SARG|gi|950834222|ref|WP_057524365.1|	27.5	200	444	648	5.14e-16	79.3
k141_91149_104	SARG|YP_002044935	27.5	200	444	648	5.14e-16	79.3
k141_91149_104	SARG|gi|487407385|ref|WP_001675419.1|	27.5	200	444	648	5.14e-16	79.3
k141_91149_104	SARG|gi|835666879|ref|WP_047606339.1|	27.5	200	444	648	5.14e-16	79.3
k141_91149_111	megares|MEG_7603|Drugs|Glycopeptide|VanD-type_accessory_protein|VANYD_1	28.3	251	436	355	1.18e-18	85.9
k141_91149_111	SARG|BAE96115	28.3	251	436	355	1.18e-18	85.9
k141_91149_111	NCBI|WP_063856854.1|1|1|vanY-D|vanY-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|transpeptidase-like_D-Ala-D-Ala_carboxypeptidase_VanY-D|AMR|glycopeptide	28.6	252	436	356	2.91e-18	84.7
k141_91149_111	megares|MEG_7604|Drugs|Glycopeptide|VanD-type_accessory_protein|VANYD_2	28.0	186	436	209	5.18e-12	63.9
k141_91149_125	SARG|ZP_03958019	57.3	295	304	317	1.41e-105	309
k141_91149_125	SARG|ZP_04528247	55.9	299	304	279	2.62e-104	305
k141_91149_125	SARG|ZP_03949893	52.9	289	304	288	5.05e-99	291
k141_91149_125	SARG|ZP_03984017	52.9	289	304	288	1.44e-98	290
k141_91149_125	SARG|ZP_04433866	52.6	289	304	288	2.89e-98	290
k141_91149_125	SARG|YP_002929946	54.3	293	304	282	1.56e-96	285
k141_91149_125	SARG|YP_002937728	54.4	296	304	289	5.58e-96	284
k141_91149_125	SARG|ZP_03938934	51.0	294	304	288	3.54e-94	279
k141_91149_125	SARG|ZP_03941859	50.7	294	304	288	1.43e-93	278
k141_91149_125	SARG|ZP_03945515	50.8	295	304	291	1.57e-93	278
k141_91149_131	SARG|gb|AAK76137.1|ARO:3000024|patA	35.4	523	583	564	8.97e-101	315
k141_91149_131	SARG|gb|AAC74000.1|ARO:3003950|msbA	27.7	570	583	582	1.23e-65	223
k141_91149_131	SARG|gb|AAK76136.1|ARO:3000025|patB	28.8	586	583	588	3.74e-65	222
k141_91149_131	SARG|gi|943909899|ref|WP_055545300.1|	28.4	574	583	601	2.49e-62	215
k141_91149_131	SARG|gi|928900436|ref|WP_053931243.1|	28.2	575	583	600	4.71e-62	214
k141_91149_131	SARG|gi|664579989|ref|WP_031094015.1|	28.2	575	583	601	4.80e-62	214
k141_91149_131	SARG|gi|517347347|ref|WP_018522839.1|	28.4	574	583	601	2.47e-61	212
k141_91149_131	SARG|gi|516795764|ref|WP_018105258.1|	28.7	575	583	601	3.42e-61	212
k141_91149_131	SARG|gi|517381192|ref|WP_018555350.1|	28.0	575	583	602	6.70e-61	211
k141_91149_131	SARG|gi|944470764|ref|WP_055701183.1|	28.0	574	583	601	1.27e-60	210
k141_91149_132	SARG|gb|AAK76136.1|ARO:3000025|patB	35.5	611	615	588	3.28e-111	344
k141_91149_132	SARG|gb|AYV52072.1|ARO:3002882|lmrD	34.9	553	615	664	3.69e-101	320
k141_91149_132	SARG|gi|493394434|ref|WP_006350564.1|	32.2	606	615	602	4.82e-94	300
k141_91149_132	SARG|gi|1033217078|gb|OAR27197.1|	31.2	615	615	601	2.91e-91	293
k141_91149_132	SARG|gi|663330365|ref|WP_030329892.1|	31.2	615	615	607	9.31e-91	291
k141_91149_132	SARG|gi|695865802|ref|WP_032778631.1|	31.2	615	615	605	1.74e-90	291
k141_91149_132	SARG|gi|517381192|ref|WP_018555350.1|	31.6	608	615	602	2.26e-90	290
k141_91149_132	SARG|gi|759527374|ref|WP_043247487.1|	31.2	615	615	605	2.44e-90	290
k141_91149_132	SARG|gi|1045390184|ref|WP_065479071.1|	31.5	615	615	605	2.44e-90	290
k141_91149_132	SARG|gi|948137056|ref|WP_056795395.1|	31.0	609	615	602	3.17e-90	290
k141_91149_135	SARG|gi|313614636|gb|EFR88215.1|	32.5	434	444	453	1.35e-69	226
k141_91149_135	SARG|gi|446573718|ref|WP_000651064.1|	32.0	428	444	451	7.01e-69	224
k141_91149_135	SARG|gi|537465183|ref|WP_020976941.1|	32.0	428	444	451	9.84e-69	224
k141_91149_135	SARG|YP_302230	30.1	428	444	451	1.38e-68	224
k141_91149_135	SARG|gi|686155635|ref|WP_031787393.1|	31.8	428	444	451	1.38e-68	224
k141_91149_135	SARG|gi|505177635|ref|WP_015364737.1|	31.1	434	444	451	1.38e-68	224
k141_91149_135	SARG|gi|446573715|ref|WP_000651061.1|	32.7	431	444	451	1.94e-68	223
k141_91149_135	SARG|gi|488374619|ref|WP_002444004.1|	31.7	429	444	452	1.99e-68	223
k141_91149_135	SARG|gi|686334333|ref|WP_031881350.1|	32.7	431	444	451	2.72e-68	223
k141_91149_135	SARG|gi|686294396|ref|WP_031862836.1|	32.7	431	444	451	2.72e-68	223
k141_91149_136	SARG|YP_302230	22.9	280	456	451	2.66e-13	70.5
k141_91149_179	SARG|YP_002333394	34.7	121	388	323	4.90e-15	74.3
k141_91149_179	SARG|AF310956.2.gene5.p01	33.9	121	388	323	1.61e-14	72.8
k141_91149_179	NCBI|WP_063856701.1|1|1|vanH-B|vanH-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|D-lactate_dehydrogenase_VanH-B|AMR|glycopeptide	33.9	121	388	323	1.61e-14	72.8
k141_91149_179	SARG|gb|AAB05626.1|ARO:3002943|vanHB	26.2	267	388	323	2.92e-14	72.0
k141_91149_179	SARG|Q47748	26.2	267	388	323	5.29e-14	71.2
k141_91149_179	SARG|gi|498515089|ref|WP_010815296.1|	26.2	267	388	323	1.29e-13	70.1
k141_91149_179	SARG|gi|985522333|ref|WP_060811962.1|	26.2	267	388	323	1.29e-13	70.1
